<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>058 Pharmacology Ini-Cet 2023 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQs / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">34</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "text": "A patient underwent a hysterectomy and was given morphine in the post-operative period and in the ward for pain. She now presents with respiratory depression and pin point pupils. What is the drug used to treat this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Naloxone"
      },
      {
        "id": 2,
        "text": "Pethidine"
      },
      {
        "id": 3,
        "text": "Atropine"
      },
      {
        "id": 4,
        "text": "Buprenorphine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The drug of choice for the&nbsp;<strong>reversal </strong>of<strong> respiratory depression</strong> is<strong>&nbsp;naloxone</strong>.&nbsp;<strong>Naloxone</strong> is a <strong>competitive antagonist at &mu;-opioid receptors</strong> and rapidly reverses the effects of opioid toxicity when administered.</p>\n<p>Opioid overdose <strong>symptoms</strong>:</p>\n<ul>\n<li>Triad of coma, respiratory depression, and pinpoint pupils (miosis).</li>\n<li>Hypotension, bradycardia</li>\n<li>Shallow breathing</li>\n<li>Hypothermia</li>\n</ul>\n<p>Naloxone is a pure opioid antagonist which reverses all effects,<strong>&nbsp;except sedation</strong>.&nbsp;Naloxone is also used for reversing neonatal asphyxia due to opioid usage in labor.</p>\n<p>Other options</p>\n<p>Option B -&nbsp;<strong>Meperidine (pethidine)</strong>&nbsp;is a&nbsp;<strong>mu-opioid receptor</strong>&nbsp;(MOR)<strong>&nbsp;agonist</strong>. It has a&nbsp;<strong>strong analgesic</strong>&nbsp;effect on the&nbsp;<strong>central nervous system</strong>.&nbsp;It is mainly used as an<strong>&nbsp;analgesic&nbsp;</strong>but can also be used in post-anesthetic shivering.&nbsp;It has a greater ability to enter the CNS and produce analgesia at lower systemic concentrations compared to morphine. Therefore,&nbsp;<strong>constipation</strong>, urinary retention, and nausea are&nbsp;<strong>less</strong>&nbsp;frequent compared to morphine.</p>\n<p>Meperidine can cross the placenta and cause significant&nbsp;<strong>respiratory depression</strong>&nbsp;in the fetus.&nbsp;In patients or addicts who are tolerant to the depressant effects of meperidine, large doses repeated at short intervals may produce an&nbsp;<strong>excitatory syndrome</strong>&nbsp;that includes hallucinations, tremors, muscle twitches, etc.</p>\n<div class=\"ng-scope\">Option C -<strong>Atropine</strong> is an&nbsp;<strong>anticholinergic</strong>&nbsp;drug. It acts through&nbsp;<strong>reversible, competitive inhibition</strong>&nbsp;of the postsynaptic muscarinic acetylcholine receptors. It is indicated in the treatment of organophosphate/muscarinic poisoning, in bradycardia, and to reduce salivary secretions.\n<p>The adverse effects of atropine are due to the antimuscarinic effects, including xerostomia, blurring of vision, photophobia, tachycardia, flushing, warm, dry skin, constipation, urinary retention, anhidrosis, delirium, and coma. Intoxication with atropine results in all the above symptoms along with convulsions, and circulatory collapse due to respiratory failure. Death may occur secondary to respiratory paralysis.</p>\n</div>\n<p>Option D -&nbsp;<strong>Buprenorphine</strong>&nbsp;is a&nbsp;<strong>partial&nbsp;&mu; agonist</strong>&nbsp;and an&nbsp;<strong>antagonist</strong>&nbsp;at&nbsp;<strong>&delta;</strong>&nbsp;and&nbsp;<strong>&kappa;</strong>&nbsp;receptors. It is used as an analgesic and in the management of opioid dependence.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Drug used for trastuzumab-resistant her 2 positive breast cancer is:",
    "choices": [
      {
        "id": 1,
        "text": "Vismodegib"
      },
      {
        "id": 2,
        "text": "Lapatinib"
      },
      {
        "id": 3,
        "text": "Vemurafenib"
      },
      {
        "id": 4,
        "text": "Erlotinib"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Lapatinib</strong> is used for <strong>trastuzumab-resistant HER-2 neu-positive breast carcinoma</strong>.</p>\n<p>Lapatinib is an orally bioavailable, small-molecule<strong> inhibitor of the EGFR and HER2 tyrosine kinases</strong>. Lapatinib is metabolized by <strong>CYP3A4</strong>.</p>\n<div class=\"page\" title=\"Page 1406\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 1406\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 1406\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Lapatinib</strong> in combination<strong> with capecitabine</strong> is approved for the treatment of patients with<strong> metastatic HER2-positive trastuzumab-refractory breast cancer.</strong> <strong>Lapatinib</strong> is also used in combination<strong> with </strong>the aromatase inhibitor <strong>letrozole</strong> to treat<strong> postmenopausal women with hormone receptor-positive, metastatic breast cancer that overexpresses HER2.</strong></p>\n<div class=\"page\" title=\"Page 1406\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Frequent<strong> adverse effects</strong> include acneiform rash, diarrhea, cramping, and exacerbation of gastroesophageal reflux.<strong> Cardiac toxicity</strong> appears less pronounced than with trastuzumab, although lapatinib should be used with caution in combination with cardiotoxic drugs. A dose-dependent <strong>prolongation</strong> of the <strong>QT interval</strong> has been reported; thus, careful monitoring of patients with heart disease is recommended. <strong>Hepatotoxicity</strong> that may be severe has been observed.</p>\n<p><strong>Trastuzumab</strong>&nbsp;is a monoclonal antibody that<strong> inhibits the HER2 receptor</strong>. It is used in the <strong>treatment of HER2-positive breast cancer.</strong></p>\n<p>Other options:</p>\n<p><strong>Option A:&nbsp;</strong><strong>Vismodegib</strong>&nbsp;is a&nbsp;<strong>hedgehog pathway inhibitor</strong>&nbsp;used to treat&nbsp;<strong>metastatic and locally advanced BCCs</strong>.</p>\n<p><strong>Option C</strong>:&nbsp;<strong>Vemurafenib</strong>&nbsp;is a&nbsp;<strong>BRAF inhibitors</strong>&nbsp;used in metastatic melanoma and thyroid cancers with BRAF V600E mutation.</p>\n<p><strong>Option D</strong>:&nbsp;<strong>Erlotinib</strong>&nbsp;is a protein kinase antagonists which is the first line treatment of&nbsp;<strong>non-small cell lung carcinoma</strong>&nbsp;with EGFR deletion of exon 19 or L858R mutation</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Nomogram used for vancomycin dosing is?",
    "choices": [
      {
        "id": 1,
        "text": "Salazar"
      },
      {
        "id": 2,
        "text": "Halsted"
      },
      {
        "id": 3,
        "text": "Rummack-mathew"
      },
      {
        "id": 4,
        "text": "Matzke"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The nomogram used for <strong>vancomycin dosing</strong> is the&nbsp;<strong>Matzke nomogram.</strong></p>\n<p>The Matzke nomogram includes <strong>dosing intervals </strong>ranging from 0.5 to 12 days on a continuum of CL<sub>cr</sub>(<strong>Creatinine clearance</strong>) values from 0 to 120 mL/min. It is designed to<strong> guide </strong>the <strong>determination of the initial empiric dose </strong>and <strong>interval of intravenous (IV) vancomycin</strong> in <strong>hospitalized adults</strong> who are<strong> not receiving hemodialysis</strong>.&nbsp;The nomogram does not apply to patients who exhibit highly variable vancomycin pharmacokinetics. These patients include the critically ill, those with burn injuries affecting more than 20 percent of their body surface, patients with rapidly changing renal function, pregnant women, those with liver failure/ascites, individuals at the extremes of weight, patients who are acutely post-transplant, and those with cystic fibrosis</p>\n<p>The <strong>Rumack-Matthew nomogram </strong>uses the serum acetaminophen concentration,&nbsp;in relation to the&nbsp;time after ingestion, to <strong>assess potential hepatotoxicity</strong>&nbsp;after a&nbsp;single, acute ingestion of <strong>acetaminophen</strong>.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is true statement regarding lithium?",
    "choices": [
      {
        "id": 1,
        "text": "It is not absorbed from the stomach"
      },
      {
        "id": 2,
        "text": "It can cause fine tremors in the therapeutic range"
      },
      {
        "id": 3,
        "text": "Approved for the treatment of absent seizures"
      },
      {
        "id": 4,
        "text": "It is not teratogenic"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The true statement about <strong>lithium</strong> is it can<strong> cause fine tremors in the therapeutic range.</strong></p>\n<p>Lithium has a very narrow therapeutic index of&nbsp;<strong>0.8-1.2 mEq/L.</strong>&nbsp;The severity of lithium toxicity is often divided into the following three grades:&nbsp;</p>\n<table style=\"height: 351px;\" width=\"495\">\n<tbody>\n<tr>\n<td style=\"width: 111.148px;\"><strong>Grade</strong></td>\n<td style=\"width: 165.289px;\">\n<p><strong>Sr. lithium concentration&nbsp;</strong>(in mEq/L)</p>\n</td>\n<td style=\"width: 196.562px;\"><strong>Symptoms</strong></td>\n</tr>\n<tr>\n<td style=\"width: 111.148px;\"><strong>Mild symptoms</strong></td>\n<td style=\"width: 165.289px;\"><strong>1.5-2.5&nbsp;</strong></td>\n<td style=\"width: 196.562px;\">Nausea, vomiting,&nbsp;<strong>tremor</strong>, and fatigue</td>\n</tr>\n<tr>\n<td style=\"width: 111.148px;\"><strong>Moderate intoxication</strong></td>\n<td style=\"width: 165.289px;\"><strong>2.5-3.5&nbsp;</strong></td>\n<td style=\"width: 196.562px;\"><strong>Confusion</strong>, agitation, delirium, tachycardia, and hypertonia</td>\n</tr>\n<tr>\n<td style=\"width: 111.148px;\"><strong>Severe intoxication</strong></td>\n<td style=\"width: 165.289px;\"><strong>&gt;3.5&nbsp;</strong></td>\n<td style=\"width: 196.562px;\">Coma,&nbsp;<strong>seizures</strong>, hyperthermia, and hypotension</td>\n</tr>\n</tbody>\n</table>\n<p>A fine tremor is common in patients taking lithium at therapeutic doses.&nbsp;Therapeutic lithium tremor is generally symmetric, limited to the arms, and nonprogressive. The tremor from&nbsp;<strong>lithium toxicity</strong>&nbsp;is&nbsp;<strong>coarser</strong>&nbsp;and&nbsp;<strong>more disabling</strong>, may also affect the legs, and occurs with other symptoms of toxicity.&nbsp;Other adverse effects include&nbsp;mental confusion,&nbsp;<strong>hypothyroidism</strong>,&nbsp;<strong>nephrogenic</strong>&nbsp;<strong>diabetes insipidus,</strong>&nbsp;and&nbsp;edema. Lithium use in early pregnancy causes&nbsp;<strong>Ebstein anomaly</strong>&nbsp;in the fetus<strong>(Option D)</strong>. Fetal lithium exposure is associated with&nbsp;<strong>neonatal goiter, CNS depression, hypotonia (floppy baby syndrome), and cardiac murmur.</strong></p>\n<p>As lithium is readily dialyzed, lithium overdose or toxicity is treated with&nbsp;<strong>hemodialysis</strong>.</p>\n<p><strong>Lithium</strong>&nbsp;is a&nbsp;<strong>mood stabilizer</strong>&nbsp;with a very narrow therapeutic index. Lithium is administered <strong>orally</strong>. Lithium is almost<strong> completely absorbed</strong> from the GI tract(<strong>Option A</strong>). It is the&nbsp;<strong>first line</strong>&nbsp;of management in&nbsp;<strong>bipolar disorder</strong>.</p>\n<p>Lithium is also&nbsp;<strong>used</strong> in the <strong>management</strong> of <strong>mania and has anti-suicidal properties. (Option C)</strong> It has a narrow therapeutic index, and blood levels in excess of this may cause symptoms of toxicity. <strong>Therapeutic drug monitoring</strong> is done by measuring lithium <strong>levels 12 hours after the last dose</strong>.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following",
    "choices": [
      {
        "id": 1,
        "text": "A-2, B-3, C-4, D-1"
      },
      {
        "id": 2,
        "text": "A-3, B-4, C-1, D-2"
      },
      {
        "id": 3,
        "text": "A-4, B-2, C-3, D-1"
      },
      {
        "id": 4,
        "text": "A-1, B-2, C-3, D-4"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<table style=\"width: 240.562px; height: 165px;\">\n<tbody>\n<tr style=\"height: 33px;\">\n<td style=\"width: 116px; height: 33px;\">A. Mirabegron</td>\n<td style=\"width: 101.562px; height: 33px;\">&nbsp;3. Beta 3</td>\n</tr>\n<tr style=\"height: 28px;\">\n<td style=\"width: 116px; height: 28px;\">B. Indacaterol</td>\n<td style=\"width: 101.562px; height: 28px;\">&nbsp;4. Beta 2</td>\n</tr>\n<tr style=\"height: 30px;\">\n<td style=\"width: 116px; height: 30px;\">C. Betaxolol</td>\n<td style=\"width: 101.562px; height: 30px;\">&nbsp;1. Beta 1</td>\n</tr>\n<tr style=\"height: 31.5px;\">\n<td style=\"width: 116px; height: 31.5px;\">D. Isoproterenol</td>\n<td style=\"width: 101.562px; height: 31.5px;\">&nbsp;2. Beta&nbsp;</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Mirabegron</strong>&nbsp;is a&nbsp;<strong>&beta;3-adrenergic receptor agonist</strong>&nbsp;which is used for&nbsp;<strong>bladder incontinence</strong>. Activation of this receptor in the bladder leads to detrusor muscle relaxation and increased bladder capacity. This action prevents voiding and provides relief for those with an overactive bladder and urinary incontinence.&nbsp;</p>\n<p><strong>Indacaterol</strong> is a very long acting beta 2 agonists<strong>&nbsp;(V-LABA)&nbsp;</strong>and can be used once daily in COPD maintenance<strong>.</strong></p>\n<p><strong>Betaxolol </strong>is a &beta;<sub>1</sub>&nbsp;selective third-generation &beta;-blocker with additional <strong>calcium entry blockade</strong> activity and a slight membrane-stabilizing property. It does not have agonist activity.</p>\n<p><strong>Isoproterenol</strong> is a<strong>&nbsp;non-selective beta agonist (&beta;<sub>1</sub>=&beta;<sub>2</sub>) with no&nbsp;&alpha; action</strong>. The direct action on cardiac&nbsp;<strong>&beta;<sub>1</sub></strong>&nbsp;receptors causes an increased risk of&nbsp;<strong>tachycardia</strong>&nbsp;and arrhythmias. The decrease in peripheral vascular resistance is due to&nbsp;<strong>&beta;<sub>2</sub></strong>&nbsp;action causing a<strong>&nbsp;fall in diastolic blood pressure.</strong>&nbsp;Isoproterenol currently may be used as a<strong>&nbsp;cardiac stimulant</strong>&nbsp;in patients with<strong>&nbsp;bradycardia or heart block,&nbsp;</strong>particularly in anticipation of inserting an artificial cardiac pacemaker.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "True about therapeutic index of a drug is:",
    "choices": [
      {
        "id": 1,
        "text": "Denotes safety and efficacy after experiments on humans"
      },
      {
        "id": 2,
        "text": "Denotes safety and efficacy in the population"
      },
      {
        "id": 3,
        "text": "Denotes safety and efficacy in an individual"
      },
      {
        "id": 4,
        "text": "Ratio of median lethal dose in 50% of population to median effective dose in 50% of population"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The therapeutic index of a drug denotes the <strong>safety and efficacy</strong> of the drug in the <strong>population</strong> (option B), not the individual (option C).</p>\n<p>The therapeutic index is calculated with the following equations:</p>\n<p>LD<sub>50</sub>/ED<sub>50</sub> or TD<sub>50</sub>/ED<sub>50</sub></p>\n<p>where LD<sub>50</sub> is the median lethal dose, TD<sub>50</sub> is the mean toxic dose, and ED<sub>50</sub> is the median effective dose\u00a0</p>\n<p>The <strong>therapeutic index </strong>(TI) describes a relationship between the doses of a drug that causes lethal or toxic effects with the dose that causes therapeutic effects. It is also called the therapeutic ratio. The therapeutic index is used to <strong>assess the safety </strong>of the drug administered.</p>\n<p><strong>Median lethal dose</strong> (LD<sub>50</sub>) and<strong> median toxic dose</strong> (TD<sub>50</sub>)</p>\n<ul>\n<li>LD<sub>50</sub> is the dose of the drug at which 50% of the experimental animals die</li>\n<li>In human trials, TD<sub>50</sub> can be considered. It is the dose of the drug that causes adverse effects in 50% of the population (Option D)</li>\n<li>The larger the LD<sub>50</sub> or TD<sub>50</sub>, the safer the drug\u00a0</li>\n</ul>\n<p><strong>Median effective dose</strong> (ED<sub>50</sub>) is the quantity of a drug that can produce the desired therapeutic effects in 50% of the population.</p>\n<p><strong>Therapeutic window</strong> refers to a range of concentrations at which the likelihood of efficacy is high and the probability of adverse effects is low.</p>\n<p>Note: Option D is incorrect as it does not make the necessary distinction that the therapeutic index is the ratio of the median lethal dose in 50% of animals (as the human population cannot be used for lethal studies) to the median effective dose in 50% of the population. LD<sub>50</sub> is measured in animals, not in humans. Option B is a better choice.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Osimertinib is used in NSCLC with which of the following mutation?",
    "choices": [
      {
        "id": 1,
        "text": "T790M mutation"
      },
      {
        "id": 2,
        "text": "L858R mutation"
      },
      {
        "id": 3,
        "text": "T890M mutation"
      },
      {
        "id": 4,
        "text": "M790T mutation"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<div class=\"page\" title=\"Page 1404\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The<strong> T790M mutation</strong> in the <strong>EGFR gene</strong> is known to <strong>cause resistance to first and second-generation EGFR inhibitors</strong>. <strong>Osimertinib</strong>, as a <strong>third-generation EGFR inhibitor</strong>, is effective against this resistance, hence it is often <strong>used for patients with the T790M mutation</strong> <strong>after</strong> <strong>they've progressed</strong> on first or second-generation EGFR inhibitors.</p>\n<p>The question seems to be asking specifically for the mutation that osimertinib is particularly known for being used against, and that would be the T790M mutation.</p>\n<p>Osimertinib&nbsp;is a kinase inhibitor that is approved for&nbsp;</p>\n<ul>\n<li>Patients with <strong>metastatic non small cell lung carcinoma</strong>(NSCLC)&nbsp;that has progressed <strong>after prior EGFR TKI treatment and is positive for the EGFR T790M mutation</strong>.</li>\n<li>First-line treatment of patients with <strong>metastatic NSCLC</strong> and <strong>adjuvant therapy</strong> after <strong>resection of NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations</strong></li>\n</ul>\n<div class=\"page\" title=\"Page 1404\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>So, osimertinib is used both for the L858R mutation and T790M mutation in different settings. But T790M mutation is often highlighted because of its association with resistance to first and second-generation EGFR inhibitors, and because osimertinib can overcome this resistance.</p>\n<p>Osimertinib is <strong>administered orally </strong>and&nbsp;is a <strong>substrate of CYP3A</strong>. The drug is primarily eliminated in the feces and to a lesser extent in the urine. Concurrent administration of inducers of CYP3A4 may necessitate an increase in the dose.</p>\n<div class=\"page\" title=\"Page 1405\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The<strong>&nbsp;adverse effects</strong> after osimertinib treatment are&nbsp;<strong>leukopenia</strong>,&nbsp;<strong>diarrhea</strong>, skin rash, <strong>interstitial lung disease</strong>, <strong>QTc prolongation</strong>, and left ventricular dysfunction.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient was started on a drug for mood disorder and he developed priapism. The causative drug is:",
    "choices": [
      {
        "id": 1,
        "text": "Trazodone"
      },
      {
        "id": 2,
        "text": "Venlafaxine"
      },
      {
        "id": 3,
        "text": "Bupropion"
      },
      {
        "id": 4,
        "text": "Mirtazapine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Trazodone</strong> causes <strong>priapism</strong>.&nbsp;</p>\n<p>Trazodone is an<strong> atypical&nbsp;antidepressant drug</strong>. It is a <strong>serotonin receptor antagonist</strong>. Other drugs which belong to this include <strong>nefazodone, mirtazapine, and mianserin</strong>. Low doses of trazodone (50&ndash;200 mg) have been used widely, both alone and concurrently with SSRIs or SNRIs, to treat <strong>insomnia</strong>. Trazodone use is associated with <strong>priapism</strong> in rare instances. Intracavernous injection of <strong>phenylephrine</strong> can be used to <strong>treat priapism.</strong></p>\n<p>&nbsp;Other options:</p>\n<p>Option B: Venlafaxine is a&nbsp;<strong>second-line</strong>&nbsp;drug used in generalized anxiety disorder. It belongs to the class of&nbsp;serotonin-norepinephrine reuptake inhibitors&nbsp;<strong>(SNRIs).&nbsp;</strong>Venlafaxine can induce sustained diastolic hypertension (diastolic blood pressure &gt;90 mmHg at consecutive weekly visits). Venlafaxine also is associated with an increased risk of perinatal complications.</p>\n<p>Option C: Bupropion is a first-line drug used for&nbsp;<strong>nicotine cessation</strong>&nbsp;and has the added benefit of causing&nbsp;<strong>weight loss</strong>. Weight gain is commonly seen after stopping nicotine use. Hence this drug can be used in this patient as it treats both of these.</p>\n<p>Option D:&nbsp;<strong>Mirtazapine&nbsp;</strong>is used in major depressive disorder. It increases appetite and causes significant weight gain.</p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Cyclosporine-induced cholestasis is due to which receptor?",
    "choices": [
      {
        "id": 1,
        "text": "MDR 1"
      },
      {
        "id": 2,
        "text": "BRCA"
      },
      {
        "id": 3,
        "text": "MRP 1"
      },
      {
        "id": 4,
        "text": "OAT1B1"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Cyclosporine</strong> induced cholestasis is due to <strong>MDR1 transporter</strong>.</p>\n<div class=\"page\" title=\"Page 111\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>ABC transporters such as MRP2, <strong>MDR1</strong>, BCRP, BSEP, and MDR3 in the<strong> bile canalicular membrane of hepatocytes</strong> mediate the <strong>efflux (excretion) of drugs and their metabolites, bile salts, and phospholipids</strong> against a steep concentration gradient from liver to bile. This <strong>primary active transport</strong> is driven by <strong>ATP hydrolysis</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<p>Cyclosporine, an <strong>MDR1 substrate&nbsp;</strong>can cause cholestatic liver injury through the following mechanisms:</p>\n<ul>\n<li><strong>Competitive inhibition of ATP dependent transporters.</strong></li>\n<li><strong>Inhibition</strong> of <strong>intrahepatic vesicle transport</strong> and targeting of ATP dependent transporters to the canalicular membrane.</li>\n<li><strong>Impairment of bile secretion</strong> partly by <strong>increasing canalicular membrane fluidity</strong> without affecting the expression of canalicular transporters.&nbsp;</li>\n</ul>\n<p><strong>Cyclosporine</strong> is an immunomodulatory drug that&nbsp;<strong>inhibits calcineurin activity</strong> by<strong>&nbsp;</strong>forming a complex with <strong>cyclophilin</strong>, a cytoplasmic-receptor protein present in target cells, to form a <strong>cyclosporine-cyclophilin complex</strong>.Calcineurin is a calcium/calmodulin-dependent phosphatase required for the induction of T cell lymphokine production and proliferation.</p>\n<p>This drug-receptor complex specifically and competitively binds to and <strong>inhibits calcineurin</strong>, a calcium and calmodulin-dependent phosphatase. This, in turn, inhibits the translocation of a family of transcription factors (NF-AT), leading to reduced transcriptional activation of cytokine genes for interleukin (IL)-2, tumor necrosis factor (TNF)-alpha, IL-3, IL-4, CD40L, granulocyte-macrophage colony-stimulating factor, and interferon-gamma. Ultimately, the proliferation of T lymphocytes is reduced, resulting in <strong>immunomodulation.</strong></p>\n<p>Its uses are as follows:</p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\">In solid organ transplantation, to prevent organ rejection in kidney, liver, and heart allogeneic transplants</li>\n<li style=\"font-weight: 400;\" aria-level=\"1\">In patients with rheumatoid arthritis, when the disease has not adequately responded to methotrexate</li>\n<li style=\"font-weight: 400;\" aria-level=\"1\">Cyclosporine reportedly is effective in Behc\u0327et&rsquo;s disease, acute ocular syndrome, endogenous uveitis, atopic dermatitis, inflammatory bowel disease, and nephrotic syndrome.</li>\n</ul>\n<p>Adverse effects of cyclosporine include a <strong>decrease</strong> in glomerular filtration rate (<strong>GFR</strong>)&nbsp;and <strong>metabolic disturbances</strong> like hypomagnesemia, hyperkalemia, dyslipidemia, gynecomastia, hypertrichosis; <strong>neurotoxicity</strong> in the form of convulsions.&nbsp;There is an increased risk of developing skin and lymphoproliferative malignancies in cyclosporine-treated psoriasis patients.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A diabetic patient was started on a drug that decreased her HbA1C from 7.6 to 6.7. She started complaining of itching around vulvovaginal area . What was the most likely drug she was started on?",
    "choices": [
      {
        "id": 1,
        "text": "Acarbose"
      },
      {
        "id": 2,
        "text": "Canagliflozin"
      },
      {
        "id": 3,
        "text": "Linagliptin"
      },
      {
        "id": 4,
        "text": "Liraglutide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>In the above clinical scenario, the most likely cause of itching around the vulvovaginal area is&nbsp;<strong>canagliflozin</strong>. The&nbsp;side effects associated with canagliflozin are <strong>urinary tract infections</strong>,&nbsp;<strong>genital mycotic infections</strong> due to the high glucose content of the urine,&nbsp;<strong>increased risk of fractures</strong>, and <strong>lower extremity amputations</strong>.</p>\n<p>Canagliflozin is a <strong>sodium-glucose transporter 2</strong> (SGLT-2) <strong>inhibitor</strong>. Other SGLT-2 inhibitors include dapagliflozin and empagliflozin. They act by&nbsp;inhibiting the&nbsp;SGLT-2 transporter which is present on the <strong>proximal</strong> segment of the <strong>renal tubule</strong>. It is responsible for the reabsorption of 80-90% of filtered glucose.&nbsp;It&nbsp;inhibits glucose reabsorption resulting in glycosuria and a change in the renal threshold.</p>\n<p>SGLT2 inhibitors can cause <strong>mild weight loss</strong> and reduction in blood pressure. Drugs like&nbsp;empagliflozin and canagliflozin are found to <strong>reduce</strong> major <strong>cardiovascular events</strong>.</p>\n<p>The common side effects include <strong>urinary tract infections</strong> and<strong> genital mycotic infections</strong> due to the high glucose content of the urine.&nbsp;There is a risk of the development of <strong>diabetic ketoacidosis</strong>. It increases the <strong>risk of fractures</strong> and <strong>lower limb amputations</strong> due to the creation of an imbalance with the minerals and circulating parathormone and vitamin D. Since SGLT2 inhibitors depend on the rate of glucose filtration to be effective, potency decreases if given in stage 3 kidney disease (GFR 60&ndash;30 mL/min).</p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Acarbose is an a</strong><strong>lpha-glucosidase inhibitor. </strong>It&nbsp;reduces the intestinal absorption of glucose by inhibiting the intestinal brush border enzyme, alpha-glucosidase. These drugs also increase GLP-1 levels in circulation. They&nbsp;<strong>reduce post-prandial glucose</strong>&nbsp;levels.</p>\n<p>Option C:&nbsp;<strong>Linagliptin</strong>&nbsp;is a&nbsp;<strong>dipeptidyl-peptidase-4&nbsp;</strong>(DPP-4)<strong>&nbsp;inhibitor</strong>. It is used in type 2 diabetes as monotherapy or in combination therapy when metformin is not tolerated or contraindicated. It&nbsp;binds extensively to plasma proteins and is cleared<strong>&nbsp;primarily by the hepatobiliary system.&nbsp;</strong>Hence, no dosage adjustment is needed in renal failure.&nbsp;<strong>Dipeptidyl peptidase-4 inhibitors&nbsp;</strong>enhance the release of insulin postprandially, decrease glucagon, and thereby lower mealtime as well as fasting glucose. They are weight neutral.</p>\n<p>Option D:&nbsp;<strong>Liraglutide</strong>&nbsp;is also a&nbsp;<strong>GLP-1 receptor agonist</strong>&nbsp;and is given only in the&nbsp;<strong>subcutaneous injectable</strong>&nbsp;form. It was recently approved in the treatment of&nbsp;<strong>obesity.</strong></p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An anti-diabetic drug causes a decrease in HbA1C by causing an increase in GIP and GLP-1 levels and a decrease in glucagon levels. It is an oral drug causing a reduction in both pre and post-prandial glucose. The drug is:",
    "choices": [
      {
        "id": 1,
        "text": "Pramlinitide"
      },
      {
        "id": 2,
        "text": "Alogliptin"
      },
      {
        "id": 3,
        "text": "Liraglutide"
      },
      {
        "id": 4,
        "text": "Metformin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Alogliptin</strong> is a\u00a0<strong>dipeptidyl peptidase-4 (DPP) inhibitor.</strong> <strong>Glucagon-like peptide (GLP) and glucose-dependent insulinotropic polypeptide (GIP)</strong> are both <strong>incretins</strong> that promote the exocytosis of insulin into circulation. Both these <strong>incretins</strong> are<strong> rapidly inactivated</strong> by <strong>dipeptidyl peptidase</strong>. So, <strong>inhibition of dipeptidyl peptidase</strong> <strong>enhances</strong> the action of <strong>incretins</strong> and facilitates insulin release.\u00a0<strong>Dipeptidyl peptidase-4 inhibitors\u00a0</strong>enhance the release of insulin postprandially, decrease glucagon, and thereby lower mealtime as well as fasting glucose.\u00a0</p>\n<p>Other DPP-4 inhibitors include <strong>saxagliptin, linagliptin, alogliptin,</strong> and <strong>vildagliptin.\u00a0</strong>They are weight neutral.</p>\n<p>DPP-4 inhibitors are associated with<strong> severe</strong><strong>\u00a0joint pain which</strong> reduces on discontinuation of the drug. Linagliptin is cleared primarily by hepatobiliary system, with little renal clearance. Only saxagliptin is metabolized by the liver and must be used in lower doses if used along with a cytochrome p450 enzyme inhibitor drug. Other drugs are renally excreted and hence must be used with <strong>caution</strong> in\u00a0<strong>renal insufficiency.</strong></p>\n<p>Other options:</p>\n<p>Option A -\u00a0<strong>Pramlintide</strong>\u00a0is an\u00a0<strong>amylin agonist</strong>. It reduces postprandial glycemia and leads to\u00a0<strong>weight loss</strong>.</p>\n<p>Option C -\u00a0<strong>Liraglutide</strong>\u00a0is also a\u00a0<strong>GLP-1 receptor agonist</strong>\u00a0and is given only in the\u00a0<strong>subcutaneous injectable</strong>\u00a0form. It was recently approved for the treatment of\u00a0<strong>obesity.</strong></p>\n<p>Option D -\u00a0<strong>Metformin</strong> belongs to the\u00a0<strong>biguanides</strong>\u00a0class of oral hypoglycemic agents. It acts by activation of AMP-dependent protein kinase (<strong>AMPK</strong>). This results in reduced hepatic glucose production.\u00a0<strong>Side effects</strong>\u00a0of\u00a0<strong>metformin</strong>\u00a0are\u00a0<strong>l</strong><strong>actic acidosis,\u00a0</strong>gastrointestinal disturbance, and\u00a0<strong>vitamin B12 deficiency.</strong></p>\n<div class=\"ng-star-inserted\">\u00a0</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "What is true about keynote 189 trial?",
    "choices": [
      {
        "id": 1,
        "text": "Pembrolizumab plus chemotherapy used in NSCLC"
      },
      {
        "id": 2,
        "text": "Pembrolizumab used in NSCLC"
      },
      {
        "id": 3,
        "text": "Nivolumab plus chemotherapy used in NSCLC"
      },
      {
        "id": 4,
        "text": "Nivolumab is used in NSCLC"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Keynote 189 trial is a <strong>efficacy and safety study of</strong> <strong>pembrolizumab and chemotherapy in metastatic non-small cell carcinoma of lung.</strong></p>\n<p>Keynote 189 trial is an <strong>efficacy and safety study of pembrolizumab</strong> (MK-3475) <strong>combined with pemetrexed/platinum chemotherapy</strong> versus pemetrexed/platinum chemotherapy alone in participants <strong>with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)</strong> who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned to receive pembrolizumab combined with pemetrexed/platinum.</p>\n<p class=\"a-article-h2 f-h12\"><strong><span style=\"font-size: 12pt;\">Methods</span></strong></p>\n<p class=\"f-body\">In this <strong>double-blind, phase 3 trial</strong>, patients were <strong>randomly assigned</strong> (in a 2:1 ratio). 616 patients with metastatic nonsquamous NSCLC without sensitizing <em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression. The primary endpoints were overall survival and progression-free survival, as assessed by a blinded, independent central radiologic review.</p>\n<p class=\"a-article-h2 f-h12\"><strong><span style=\"font-size: 12pt;\">Conclusions</span></strong></p>\n<p class=\"f-body\"><span class=\"O1056PNEJMcme1801005DONENA2rxbnh O1056PNEJMcme1801005DONENB2rxbng O1056PNEJMcme1801005DONENC2rxbnf O1056PNEJMcme1801005DONEND2rxbne \">In patients with previously untreated metastatic nonsquamous NSCLC without&nbsp;<em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations, the addition of <strong>pembrolizumab</strong> to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly<strong> longer overall survival and progression-free survival than chemotherapy alone.</strong></span><strong>&nbsp;</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not a mechanism for thalidomide teratogenicity?",
    "choices": [
      {
        "id": 1,
        "text": "Release of reactive oxygen species and free radicles"
      },
      {
        "id": 2,
        "text": "Supression of angiogenesis"
      },
      {
        "id": 3,
        "text": "Cereblon binding"
      },
      {
        "id": 4,
        "text": "Inhibition of IL2, IL4, IL5"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Thalidomide</strong> does <strong>not cause</strong> teratogenicity by <strong>inhibition of IL2, IL4, and IL5.</strong></p>\n<p>The mechanism of thalidomide teratogenicity include\u00a0<strong>oxidative stress, anti-angiogenesis,</strong> and thalidomide-binding protein, <strong>cereblon </strong>which has a role in the development of cerebral tissues and because its expression in the hippocampus among other areas is associated with <strong>memory and learning processes (CRBN).\u00a0</strong>Fetal thalidomide exposure causes phocomelia. This disorder is associated with <strong>underdeveloped limbs</strong> and <strong>absent pelvic bones.</strong> Both <strong>upper</strong> and <strong>lower</strong> limbs are <strong>affected</strong>, and a part of the limbs may be missing. Fused fingers and missing thumbs are also seen. Thalidomide was originally used for the treatment of <strong>pregnancy-associated morning sickness</strong> but was <strong>withdrawn</strong> due to this adverse effect.\u00a0It is now used for the treatment of erythema nodosum leprosum.</p>\n<div class=\"page\" title=\"Page 1423\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Thalidomide is an immunomodulator. Thalidomide absorption from the GI tract is slow and highly variable. It distributes throughout most tissues and organs, without significant binding to plasma proteins. Thalidomide and its metabolites are excreted in the urine, while the <strong>nonabsorbed</strong> portion of the drug is <strong>excreted unchanged in feces</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<p>\u00a0Common adverse effects of thalidomide include sedation and constipation. However, one of the most serious adverse effects is <strong>peripheral sensory neuropathy</strong>, characterized by <strong>asymmetrical, painful, peripheral paresthesia with sensory loss</strong>. Symptoms often present as numbness of the toes and feet, muscle cramps, weakness, signs of pyramidal tract involvement, and carpal tunnel syndrome.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which is a rare but very severe side effect of clozapine that requires regular monitoring?",
    "choices": [
      {
        "id": 1,
        "text": "Suicidal tendency"
      },
      {
        "id": 2,
        "text": "Agranulocytosis"
      },
      {
        "id": 3,
        "text": "Myocarditis"
      },
      {
        "id": 4,
        "text": "Cerebral bleeding"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p class=\"p1\"><strong>Agranulocytosis</strong> is a&nbsp;rare but very severe side effect of <strong>clozapine</strong> that <strong>requires regular monitoring.&nbsp;</strong></p>\n<p class=\"p1\"><span style=\"font-size: 10pt;\">A patient who is on clozapine should undergo <strong>regular hematological monitoring</strong> due to the risk of <strong>agranulocytosis</strong>. Avoid combining clozapine with other agranulocytosis-causing drugs like carbamazepine, phenytoin, propylthiouracil, and sulfonamides.</span></p>\n<p class=\"p1\"><span style=\"font-size: 10pt;\">Adverse effects of clozapine are:</span></p>\n<ul>\n<li class=\"p1\"><span style=\"font-size: 10pt;\">Sedation and weight gain- H<sub>1</sub> antagonism</span></li>\n<li class=\"p1\"><span style=\"font-size: 10pt;\">Syncope, tachycardia, hypotension-&nbsp;&alpha;<sub>1</sub> antagonism</span></li>\n<li class=\"p1\"><span style=\"font-size: 10pt;\">Hypersalivation/sialorrhea- M<sub>4&nbsp;</sub>agonism</span></li>\n<li class=\"p1\"><span style=\"font-size: 10pt;\">Seizures- dose-dependant</span></li>\n<li class=\"p1\"><span style=\"font-size: 10pt;\">Agranulocytosis- dose-independent</span></li>\n</ul>\n<p><span style=\"font-size: 10pt;\">Clozapine reduces the seizure threshold thus<strong> increasing</strong> the risk of <strong>seizures.&nbsp;</strong></span><span style=\"font-size: 10pt;\">Clozapine, an atypical antipsychotic, is an antagonist of 5HT<sub>2A</sub>, D<sub>1</sub>, D<sub>3</sub>, D<sub>4,&nbsp;</sub>and&nbsp;&alpha;-receptors.&nbsp;</span><span style=\"font-size: 10pt;\">Clozapine is used in <strong>treatment-resistant</strong> <strong>schizophrenia, suicidal patients with schizophrenia,</strong> severe psychotic depression, and Huntington's disease. &nbsp;</span></p>\n<p>&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following newly approved anti-diabetic drugs can be given for heart failure with reduced ejection fraction and impaired renal function?",
    "choices": [
      {
        "id": 1,
        "text": "Empaglifozin"
      },
      {
        "id": 2,
        "text": "Degludec"
      },
      {
        "id": 3,
        "text": "Linagliptin"
      },
      {
        "id": 4,
        "text": "Rosiglitazone"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Empaglifozin</strong>, which is a <strong>sodium-glucose transporter-2 (SGLT-2) inhibitor</strong> has been recently approved for use in patients with <strong>Heart Failure with Reduced Ejection Fraction</strong>, and can be initiated in patients with <strong>impaired renal function</strong> with <strong>estimated glomerular filtration rate &gt; 20 mL/min/1.73</strong> <strong>m2</strong>.</p>\n<p>Empagliflozin works by inhibiting the sodium-glucose co-transporter-2 <strong>(SGLT-2)</strong> in the <strong>proximal renal tubules</strong> resulting in <strong>reduced reabsorption</strong> and <strong>increased urinary excretion of glucose</strong>. The<strong> glucose-lowering</strong> effect is <strong>independent of insulin</strong>. Empagliflozin acts as a <strong>diuretic</strong> and <strong>natriuretic</strong> by reducing sodium and volume load, causing intravascular contraction. Empagliflozin is also associated with <strong>weight loss</strong>, with <strong>reductions in blood pressure</strong> without increasing heart rate. Empagliflozin has been found to <strong>decrease the risk of mortality</strong> from <strong>cardiovascular causes in diabetic patients</strong>.\u00a0<br /><br />SGLT-2 inhibitors have a <strong>cardioprotective effect</strong> resulting from<strong> improved cardiac cell metabolism</strong>,<strong> improvement of ventricular loading mechanism</strong>, <strong>reduction of cardiac cell necrosis</strong> and <strong>fibrosis</strong>. It also has a <strong>renoprotective</strong> property.</p>\n<p><strong>Except for empaglifozin</strong> which <strong>can be used in chronic kidney disease</strong>, use of <strong>other SGLT-2 inhibitors might lead to acute kidney injury</strong> and should be avoided in patients with renal failure. <strong>Side effects </strong>of\u00a0<strong>empaglifozin\u00a0</strong>includes\u00a0<strong>dehydration, euglycemic diabetic ketoacidosis, urinary tract infections, genital mycotic infections, hypoglycemia and necrotizing fasciitis.</strong><br /><br /><strong>Side</strong> <strong>effects</strong> of <strong>SGLT-2 inhibitors</strong> include <strong>dehydration</strong>, <strong>hyperkalemia</strong>, <strong>worsening of diabetic ketoacidosis</strong>, increased risk of <strong>fractures</strong>, <strong>leg and foot amputation</strong> with <strong>canagliflozin</strong>, and a possible increased risk of <strong>bladder cancer with dapagliflozin</strong>. <strong>Dapagliflozin</strong> has also been recently approved by the FDA for treatment of <strong>Heart failure with Reduced Ejection Fraction</strong> in both <strong>diabetic and non-diabetic</strong> patients, it has been associated with <strong>increased risk</strong> of <strong>bladder cancer</strong> and<strong> breast cancer</strong>.\u00a0<br /><br /><strong>Other options :\u00a0<br /><br /></strong>Option B : <strong>Degludec</strong> is a form of <strong>long acting insulin</strong>, and is not indicated for the treatment of heart failure.<br /><br />Option C : <strong>Linagliptin</strong> is a\u00a0<strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong>, which <strong>enhances the action of incretins</strong> that <strong>promote the release of insulin</strong> into circulation. Dipeptidyl peptidase-4 inhibitors enhance the release of insulin postprandially,<strong> decrease glucagon</strong>, and thereby<strong> lower mealtime as well as fasting glucose</strong>. Linagliptin is<strong> safe to use in chronic kidney disease</strong> as it is cleared primarily by hepatobiliary system, but is <strong>not approved for heart failure</strong>.\u00a0<br /><br />Option D : <strong>Rosiglitazone</strong> is a <strong>thiazolidinedione</strong>, which <strong>activates PPAR-\u03b3 receptors </strong>in adipose tissue and skeletal muscles. These are <strong>insulin sensitizers</strong> and<strong> increase insulin-mediated glucose uptake</strong> in patients with type 2 diabetes. Rosiglitazone is <strong>currently banned in India</strong> as it has shown an increased risk of developing <strong>myocardial infarction, stroke, congestive heart failure, and death</strong>.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient diagnosed with ulcerative colitis presents with 2-3 episodes of bloody stools per day. What should be given to manage this patient ?",
    "choices": [
      {
        "id": 1,
        "text": "Budesonide"
      },
      {
        "id": 2,
        "text": "Azathioprine"
      },
      {
        "id": 3,
        "text": "6-mercaptopurine"
      },
      {
        "id": 4,
        "text": "5-aminosalicylic acid"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>5-aminosalicylic acid</strong> is is effective in <strong>inducing and maintaining remission</strong> and is considered to be the<strong> first line agents</strong> for\u00a0<strong>mild to moderate</strong> <strong>ulcerative colitis,\u00a0</strong>seen in this patient with<strong> 2-3 bloody stools per day</strong>.<br /><br /><strong>Treatment</strong> of <strong>ulcerative colitis</strong> differs based on the <strong>severity of the disease</strong> and involves medical and surgical management. Patients with <strong>mild to moderate disease</strong> are treated with <strong>topical or systemic 5-aminosalicylate drugs</strong> such as <strong>Salazopyrine/Sulfasalazine</strong> and <strong>Mesalamine (5 ASA)</strong> which are<strong> first-line therapy.</strong> <strong>Glucocorticoids (option A), immunosuppressants</strong>, and <strong>biologics</strong> are effective in patients with <strong>moderate</strong> <strong>to</strong> <strong>severe</strong> disease. <br /><br /><strong>Azathioprine </strong>and <strong>cyclosporin</strong> are used as<strong> steroid-sparing</strong> agents.<strong> Anti-TNF alpha inhibitors (infliximab, adalimumab) </strong>can be used as <strong>anti-inflammatories</strong>.</p>\n<p><strong>Surgery</strong> is recommended for patients who <strong>do not improve after medical treatment </strong>or with<strong> toxic megacolon</strong>, and <strong>perforation</strong>. Indications for <strong>elective surgery</strong> include <strong>failure of medical therapy</strong>, <strong>growth retardation</strong>,<strong> extraintestinal disease</strong>, and <strong>malignant change</strong>.<br /><br /><strong>Ulcerative colitis </strong>is an <strong>inflammatory bowel disease</strong> resulting in<strong> superficial erosions</strong> confined to the <strong>mucosa and submucosa</strong> of the colon. It <strong>starts from the rectum</strong> and extends proximally in a <strong>continuous</strong> manner. The clinical features include abdominal pain, diarrhea, <strong>rectal bleeding</strong>, tenesmus, and passage of mucus. Other symptoms include anorexia, nausea, vomiting, fever, and weight loss.<br /><br />Ulcerative colitis is <strong>graded</strong> based on the <strong>frequency of bowel movements </strong>and <strong>systemic involvement</strong>.\u00a0</p>\n<p>- <strong>Mild</strong> disease - <strong>\u22644 stools per day</strong> with/without <strong>rectal bleeding</strong>;<br />- <strong>Moderate</strong> disease - <strong>\u22654 stools per day</strong> with<strong> few systemic signs</strong> of illness;\u00a0<br />- <strong>Severe</strong> disease -<strong> \u22656 blood stools per day </strong>with <strong>fever, tachycardia (\u226590 beats/min)</strong>, <strong>anemia (hemoglobin &lt;10.5 g/dL)</strong>, and elevated levels of <strong>inflammatory markers (ESR \u226530 mm/h)</strong><br />- <strong>Fulminant</strong> disease - <strong>&gt;10 stools per day</strong> with <strong>severe anemia</strong> requiring blood transfusion and <strong>progressive colonic dilation (toxic megacolon)</strong><br /><br />Investigations show <strong>elevated C-reactive protein</strong>, <strong>platelet count, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin</strong>. A <strong>colonoscopy</strong> reveals <strong>loss of typical vascular pattern</strong>, <strong>erythema</strong>, <strong>friability</strong>, <strong>regenerative</strong> <strong>mucosal</strong> <strong>nodules</strong>, <strong>pseudopolyps</strong>, and <strong>ulcerations</strong>.\u00a0</p>\n<p><strong>Extraintestinal manifestations</strong> associated with IBD include <strong>ocular features </strong>(episcleritis, and uveitis), <strong>dermatological</strong> manifestations (erythema nodosum, pyoderma gangrenosum), <strong>rheumatological</strong> (arthropathies, sacroiliitis, ankylosing spondylitis) and <strong>primary sclerosing cholangitis</strong>. Complications include <strong>toxic megacolon</strong>, hemorrhage, strictures, and perforations. These patients are also at increased risk of <strong>colon cancer</strong>.<br /><br />Other options\u00a0<br /><br />Option B &amp; C : Azathioprine and 6-mercaptopurine are not first line agents for ulcerative colitis.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 25 year old male patient presents with several purpuric skin lesions and is diagnosed with idiopathic thrombocytopenic purpura. Which of the following tyrosine kinase inhibitors can be used in his condition?",
    "choices": [
      {
        "id": 1,
        "text": "Eltrombopag"
      },
      {
        "id": 2,
        "text": "Romiplostim"
      },
      {
        "id": 3,
        "text": "Bosutinib"
      },
      {
        "id": 4,
        "text": "Fostamatinib"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Fostamatinib</strong> is a<strong> tyrosine kinase inhibitor</strong> used in the treatment of <strong>chronic immune thrombocytopenia</strong> (<strong>idiopathic thrombocytopenic purpura</strong>).<br /><br /><strong>Fostamatinib</strong> has activity against <strong>spleen tyrosine kinase (SYK)</strong>. The <strong>major metabolite</strong> of fostamatinib, <strong>R406</strong>, <strong>inhibits signal transduction</strong> of <strong>Fc-activating receptors</strong> and <strong>B-cell receptors</strong>. The fostamatinib metabolite<strong> R406 reduces antibody-mediated destruction of platelets.<br /><br />Idiopathic thrombocytopenic purpura (ITP)</strong> is an <strong>acquired</strong> disorder characterized by the <strong>immune-mediated destruction of platelets</strong> and possibly <strong>inhibition of platelet release</strong> from the <strong>megakaryocyte</strong>. It is an autoimmune disorder caused by antibodies directed against <strong>platelet membrane glycoproteins IIb-IIIa or Ib-IX</strong>. <strong>Secondary</strong> <strong>causes</strong> of ITP include <strong>systemic lupus erythematosus (SLE)</strong>, <strong>HIV-AIDS</strong>, and <strong>Hepatitis C</strong>.</p>\n<p>ITP usually presents with <strong>mucocutaneous bleeding</strong>, <strong>very low platelet count</strong>, and <strong>normal peripheral blood cells</strong>. Patients typically exhibit <strong>ecchymoses</strong> and <strong>petechiae</strong> or they may incidentally discover <strong>thrombocytopenia</strong> during a routine complete blood count. Rarely, <strong>life-threatening bleeding</strong> may occur. The presence of <strong>wet purpura </strong>(<strong>blood blisters in the mouth</strong>) and <strong>retinal hemorrhages</strong> can serve as<strong> warning signs</strong> of potentially<strong> life-threatening bleeding</strong>.<br /><br />The treatment of ITP is as follows:</p>\n<table style=\"border-collapse: collapse; width: 100.046%; height: 380.781px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 4.59137%; height: 22.3984px;\">\u00a0</td>\n<td style=\"width: 45.632%; height: 22.3984px;\">Clinical features</td>\n<td style=\"width: 49.7767%; height: 22.3984px;\">Management</td>\n</tr>\n<tr style=\"height: 153.594px;\">\n<td style=\"width: 4.59137%; height: 153.594px;\">1.\u00a0</td>\n<td style=\"width: 45.632%; height: 153.594px;\">\n<p>Minor bleeding manifestations (and/or)</p>\n<p>Platelet count &gt; 5000/ \u03bcL</p>\n</td>\n<td style=\"width: 49.7767%; height: 153.594px;\">\n<p>Prednisone (OR)</p>\n<p>Anti-D immunoglobulin therapy - effective only in Rh-positive patients (OR)</p>\n<p>Intravenous immunoglobulin (IVIG)</p>\n</td>\n</tr>\n<tr style=\"height: 159.992px;\">\n<td style=\"width: 4.59137%; height: 159.992px;\">2.\u00a0</td>\n<td style=\"width: 45.632%; height: 159.992px;\">\n<p>Severe ITP (any of the following):</p>\n<p>- Significant GI / intracranial bleeding<br />- Platelet count &lt; 5000/\u03bcL<br />- Signs of impending bleeding (retinal or large oral mucosal bleeds)</p>\n</td>\n<td style=\"width: 49.7767%; height: 159.992px;\">\n<p>Platelet transfusion (AND)</p>\n<p>High-dose glucocorticoids (AND)</p>\n<p>IVIG / Anti-D immunoglobulins + Rituximab</p>\n</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 4.59137%; height: 22.3984px;\">3.\u00a0</td>\n<td style=\"width: 45.632%; height: 22.3984px;\">Relapse after first-line therapy</td>\n<td style=\"width: 49.7767%; height: 22.3984px;\">Splenectomy</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 4.59137%; height: 22.3984px;\">4.\u00a0</td>\n<td style=\"width: 45.632%; height: 22.3984px;\">Unresponsive to all other therapy or relapse after splenectomy</td>\n<td style=\"width: 49.7767%; height: 22.3984px;\">Thrombopoietin receptor agonists - romiplostim (subcutaneous), eltrombopag (oral)</td>\n</tr>\n</tbody>\n</table>\n<p><strong><br /></strong>Other options :\u00a0<br /><br />Option A and B: <strong>Eltrombopag</strong> and <strong>Romiplostim </strong>are\u00a0<strong>thrombopoietin (TPO) receptor agonists </strong>used in the treatment of <strong>immune thrombocytopenia</strong> which have failed to respond to conventional treatments. Both drugs act via the <strong>Mpl receptor</strong> to increase platelet counts and not via\u00a0tyrosine kinase inhibition.</p>\n<p>Option C: <strong>Bosutinib</strong> is a<strong> BCR-ABL</strong> <strong>tyrosine kinase inhibitor</strong> indicated in <strong>CML</strong>.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 40-year-old woman with multidrug-resistant tuberculosis presents with fatigue, constipation, weight gain, and neck swelling. Which of the following drugs is implicated in this case?",
    "choices": [
      {
        "id": 1,
        "text": "Pyrazinamide"
      },
      {
        "id": 2,
        "text": "Ethionamide"
      },
      {
        "id": 3,
        "text": "Cycloserine"
      },
      {
        "id": 4,
        "text": "Streptomycin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The given clinical features are suggestive of<strong> hypothyroidism with goiter,</strong> which is a known <strong>adverse effect of ethionamide</strong>.</p>\n<p><strong>Mutidrug-resistant tuberculosis (MDR-TB)</strong> is treated with <strong>2nd line agents</strong> that include <strong>ethionamide (ETH)</strong>. ETH is not a first-line agent due to its <strong>gastrointestinal side effects</strong>. Ethionamide <strong>inhibits activity of the InhA gene product</strong>, resulting in <strong>inhibition of mycolic acid synthesis</strong>. It is <strong>structurally related to thionamides</strong> (propylthiouracil and methimazole) and therefore<strong> causes hypothyroidism</strong> by <strong>preventing organification of iodine in thyroid hormone synthesis.</strong> <strong>Another antitubercular </strong>drug that can cause<strong> hypothyroidism </strong>is<strong> Para-amino salicylic acid (PAS)</strong>.\u00a0</p>\n<p>ETH/PAS-induced hypothyroidism should be<strong> treated with thyroxine replacement </strong>therapy, instead of changing the regimen. Thyroid function usually optimizes within 2 months after completing MDR therapy.<br /><br /><strong>Ethionamide</strong> also causes <strong>hepatotoxicity</strong> and <strong>neurological</strong> <strong>adverse</strong> <strong>effects</strong> and may require <strong>pyridoxine supplementation</strong>.</p>\n<p><strong>MDR-TB</strong> is when there is <strong>resistance to atleast isoniazid and rifampicin </strong>which\u00a0are the most potent first-line drugs.\u00a0The treatment of MDR-TB is curated with drugs grouped into different classes by the world health organization (WHO).</p>\n<p><strong>Group A: Levofloxacin, bedaquiline, linezolid</strong><br /><strong>Group B: Clofazimine, cycloserine</strong><br /><strong>Group C: Ethambutol, pyrazinamide, delamanid, ethionamide</strong><br /><br />In patients<strong> treated previously</strong> or with <strong>additional drug resistance</strong>, a <strong>longer MDR-TB regimen</strong> of <strong>18-20 months</strong> is recommended. Drugs belonging to <strong>group A are preferred along with one drug from group B</strong> whenever possible. A<strong> shorter regimen of 6 months</strong> including <strong>bedaquiline</strong> with other drugs can be used in <strong>patients not treated before</strong> and <strong>without extensive disease.</strong> In <strong>pregnant</strong> <strong>women</strong> with MRD-TB, drugs such as <strong>bedaquiline</strong> and <strong>delamanid</strong> should be <strong>avoided</strong>.</p>\n<p>Other options :<br /><br />Option A : <strong>Pyrazinamide inhibits fatty acid synthase-I </strong>leading to<strong> inhibition of cell membrane synthesis</strong>. Pyrazinamide causes <strong>hyperuricemia</strong> and <strong>hepatotoxicity</strong>.\u00a0<br /><br />Option C : Adverse effects of <strong>cycloserine</strong> are mainly <strong>neurological</strong>. Half of the patients on cycloserine (1g/day) experience <strong>neuropsychiatric</strong> <strong>symptoms</strong>. It ranges from <strong>headaches to psychosis, seizures, and suicidal ideas</strong>.</p>\n<p>Option D : <strong>Streptomycin</strong> is an <strong>aminoglycoside</strong> which binds to the <strong>30S ribosomal</strong> subunit and <strong>interferes with the initiation of protein synthesis</strong>. \u00a0It is a <strong>second-line agent </strong>for the treatment of active tuberculosis. Streptomycin produces <strong>ototoxicity, vestibulotoxicity, optic nerve dysfunction, including scotomas, and peripheral neuritis.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient on amitriptyline was found in an unconscious state. Which of the following does not suggest amitriptyline toxicity?",
    "choices": [
      {
        "id": 1,
        "text": "Arrhythmias"
      },
      {
        "id": 2,
        "text": "Confusion"
      },
      {
        "id": 3,
        "text": "Hypothermia"
      },
      {
        "id": 4,
        "text": "Mydriasis"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Hypothermia</strong> is <strong>not</strong> <strong>associated</strong> with <strong>amitriptyline</strong> use or <strong>tricyclic antidepressant toxicity</strong>.<br /><br /></p>\n<p><strong>Tricyclic antidepressants (TCAs)</strong> such as <strong>amitriptyline</strong> are used in the treatment of\u00a0<strong>psychotic depression</strong>, <strong>insomnia</strong>, and several <strong>pain</strong> <strong>conditions</strong>. Their <strong>mechanism of action</strong> is <strong>inhibition of norepinephrine and serotonin reuptake</strong>. They have a\u00a0<strong>quinidine-like sodium channel blockade effect</strong>\u00a0on\u00a0<strong>cardiac</strong>\u00a0conduction. Hence, they cause<strong>\u00a0QT prolongation</strong>.\u00a0Other <strong>cardiotoxic effects</strong> include <strong>atrioventricular (AV) block</strong> and<strong>\u00a0hypotension</strong>.\u00a0<strong>Rightward-axis deviation</strong>\u00a0is also an associated finding.</p>\n<p>TCA toxicity can result in\u00a0<strong>ventricular tachyarrhythmias (Option A)</strong>, <strong>status epilepticus</strong>, <strong>hyperthermia</strong>, and <strong>coma</strong>. It\u00a0can also result in\u00a0<strong>anticholinergic syndrome</strong>\u00a0due to muscarinic receptor antagonism. Symptoms include <strong>dilated pupils (Option D)</strong>, high temperature, <strong>confusion (option B)</strong>, dry mouth,\u00a0<strong>urinary retention, tachycardia</strong>, and myoclonic movements. It is managed with\u00a0<strong>intravenous sodium bicarbonate bolus (50-100 mEq)</strong>. This helps in the <strong>reversal of sodium channel blockade</strong>.\u00a0<strong>Gastric lavage</strong>\u00a0and administration of <strong>activated charcoal</strong> can be carried out in cases of <strong>recent ingestion.</strong></p>\n<p><strong>Other side effects</strong> of TCAs include\u00a0<strong>postural hypotension </strong>from\u00a0<strong>anti-alpha 1 adrenergic</strong>\u00a0action and <strong>sedation\u00a0</strong>from\u00a0<strong>anti-histaminic</strong>\u00a0action. ECG changes such as\u00a0<strong>T wave inversion\u00a0or suppression</strong> are also common.\u00a0</p>\n<p>In some cases, it can result in polymorphic ventricular tachycardias with QT prolongation known as<strong>\u00a0torsades de pointes</strong>. Recurrent episodes can be treated with\u00a0<strong>intravenous magnesium sulfate</strong>.\u00a0<br /><br /><br /></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is beneficial in reducing the painful crisis of sickle cell anemia?",
    "choices": [
      {
        "id": 1,
        "text": "Hydroxyurea"
      },
      {
        "id": 2,
        "text": "Methotrexate + leukovorin"
      },
      {
        "id": 3,
        "text": "Methionine"
      },
      {
        "id": 4,
        "text": "Eltrombopag"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Hydroxyurea</strong> is beneficial in reducing the <strong>painful vasoocclusive crisis</strong> of <strong>sickle cell anemia.</strong>\u00a0<br /><br /><strong>Hydroxyurea</strong> is a <strong>myelosuppressive agent</strong> that is effective in <strong>reducing the frequency</strong> of <strong>painful episodes</strong> like <strong>dactylitis</strong> and <strong>acute chest syndrome</strong>, <strong>decreasing the rate of hospitalization</strong>, and <strong>requirement for blood transfusion</strong>. It is <strong>safe</strong> and <strong>well-tolerated</strong> in <strong>children</strong> and <strong>infants</strong>. Hydroxyurea is approved for <strong>long-term maintenance of sickle cell disease</strong>, and is recommended for patients of <strong>all ages</strong> regardless of symptoms.\u00a0</p>\n<p>Hydroxyurea <strong>increases fetal hemoglobin</strong> levels by an unknown mechanism and <strong>interferes with the polymerization of abnormal HbS</strong>.\u00a0</p>\n<p><strong>Newer drugs</strong> for management of <strong>acute painful crisis</strong> of sickle cell anemia include <strong>L-glutamine</strong> and <strong>crizanlizumab</strong>. For individuals <strong>&gt;5 years</strong> of age with sickle cell disease who have <strong>pain despite hydroxyurea</strong> (or who <strong>cannot tolerate hydroxyurea</strong>), <strong>L-glutamine</strong> is recommended, regardless of whether they are receiving hydroxyurea. The mechanism of action of this drug, is that it <strong>reduces oxidative stress</strong> in sickle erythrocytes. <strong>Crizanlizumab</strong> is a <strong>P-selectin-blocking monoclonal antibody</strong> which is given <strong>intravenously</strong> every month to reduce acute painful episodes.</p>\n<p><strong>Sickle cell anemia</strong> is an <strong>autosomal recessive</strong> disorder that occurs due to the<strong> point mutation</strong> in the<strong> \u03b2-globin gene </strong>which results in the <strong>replacement of glutamate </strong>residue with <strong>valine</strong>. This causes the production of <strong>sickle-shaped red blood cells</strong> due to the <strong>polymerization</strong> of <strong>deoxygenated</strong> <strong>hemoglobin (HbS)</strong>. <strong>Factors</strong> that predispose to <strong>sickling</strong> are <strong>infection</strong>, <strong>dehydration</strong>, and <strong>acidosis</strong>. Sickle cell disease causes <strong>hemolytic anemia</strong> due to <strong>increased erythrocyte destruction</strong>. The anemia is generally well compensated. Complications occur due to abnormal erythrocyte configurations that increase hemoglobin polymerization leading to a <strong>painful vaso-occlusive state</strong>.\u00a0</p>\n<p><strong>Clinical features </strong>of sickle cell anemia :\u00a0</p>\n<p>- <strong>Moderately severe hemolytic anemia</strong> with <strong>jaundice</strong>.<br />- <strong>Painful bone crisis</strong> : <strong>hand-foot syndrome </strong>or <strong>dactylitis</strong> of the bones of hands and feet.<br />- <strong>Acute chest syndrome</strong> typically presents with fever, cough, chest pain, and pulmonary infiltrates.<br />- <strong>Hyposthenuria</strong> : inability to concentrate urine.<br />- <strong>Aplastic</strong> <strong>crisis</strong> stems from the infection of red cell progenitors by parvovirus B19, which causes a transient cessation of erythropoiesis and a sudden worsening of the anemia.<br />- Spleen : In children, <strong>splenic sequestration</strong> <strong>crises</strong> occur which results in <strong>splenomegaly</strong> due to<strong> red pulp congestion</strong>. In adolescence or early adulthood, <strong>autosplenectomy</strong> occurs due to splenic infarction, fibrosis, and progressive shrinkage.<br />- Increased <strong>susceptibility to infection</strong> with <strong>encapsulated</strong> <strong>organisms</strong> like pneumococcal, meningococcal, and Haemophilus influenza septicemia, but can be reduced by vaccination and prophylactic antibiotics.<br />- Other clinical features include <strong>priapism</strong>,<strong> leg ulcers, stroke, retinopathy, pigment gallstones</strong>, and <strong>growth retardation</strong>.</p>\n<p>Other options :\u00a0<br /><br />Option B : <strong>Methotrexate</strong> interferes with folate metabolism by acting as a<strong> competitive inhibitor</strong> of the enzyme <strong>dihydrofolate reductase</strong>. This starves cells for tetrahydrofolate and makes them unable to synthesize purines and thymidine monophosphate. It does not treat painful crisis of sickle cell anemia.</p>\n<p>Option C : <strong>Methionine</strong> is an <strong>essential amino acid</strong> involved in the synthesis of folate and vitamin B12. It is not used in the management of sickle cell anemia.<br /><br />Option D : <strong>Eltrombopag </strong>is a <strong>thrombopoetin analog</strong> used to treat immune thrombocytopenia. It is not used in the treatment of painful sickle cell crisis.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "What is the most useful drug to treat doxorubicin induced cardiotoxicity?",
    "choices": [
      {
        "id": 1,
        "text": "Dexrazoxane"
      },
      {
        "id": 2,
        "text": "Dexamethasone"
      },
      {
        "id": 3,
        "text": "Aprepitant"
      },
      {
        "id": 4,
        "text": "Amifostine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Dexrazoxane</strong> is the drug of choice to treat <strong>doxorubicin</strong> <strong>induced</strong> <strong>cardiomyopathy</strong>.<br /><br /><strong>Doxorubicin</strong> is an <strong>anthracycline</strong> group of anticancer antibiotics that acts by <strong>inhibiting topoisomerase II</strong>, and is known to cause <strong>cardiotoxicity</strong>. <strong>Dexrazoxane</strong> is a <strong>cardioprotective</strong> <strong>iron-chelating agent </strong>that is indicated for use along with <strong>high dose doxorubicin</strong> to <strong>avoid cardiotoxicity</strong>.\u00a0<br /><br /><strong>Dexrazoxane</strong> is currently approved to <strong>prevent or reduce anthracycline-induced cardiotoxicity</strong> in women with<strong> metastatic breast cancer </strong>who have received a <strong>total cumulative dose of doxorubicin of 300 mg/m2</strong> .</p>\n<p>Doxorubicin-induced cardiomyopathy takes two forms:</p>\n<p>- <strong>Acute</strong>: <strong>pericarditis-myocarditis syndrome</strong>, arrhythmias, ST and T wave changes in ECG. Occurs within the first 2\u20133 days, is transient and in most cases asymptomatic.<br />- <strong>Chronic</strong>: Dose dependendent <strong>dilated cardiomyopathy associated with heart failure</strong>.\u00a0</p>\n<p><strong>Doxorubicin, daunorubicin and epirubicin</strong> share <strong>similar cardiotoxicity</strong> profile. <strong>Idarubicin</strong> has<strong> least cardiotoxicity</strong> when compared to other anthracyclines.<br /><br /><strong>Endomyocardial biopsy </strong>showing <strong>vacuolar degeneration</strong> and <strong>myofibrillar</strong> <strong>loss</strong> is seen in cardiotoxicity due to anthracyclines.<br /><br /><strong>Difference</strong> between cardiotoxicity due to <strong>anthracyclins and trastuzumab</strong>:</p>\n<table style=\"border-collapse: collapse; width: 100.046%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 48.6654%;\"><strong>Anthracyclins</strong></td>\n<td style=\"width: 48.6654%;\">Trastuzumab</td>\n</tr>\n<tr>\n<td style=\"width: 48.6654%;\"><strong>Irreversible</strong></td>\n<td style=\"width: 48.6654%;\">Reversible</td>\n</tr>\n<tr>\n<td style=\"width: 48.6654%;\"><strong>Dose-dependent</strong></td>\n<td style=\"width: 48.6654%;\">Not dose-dependent</td>\n</tr>\n<tr>\n<td style=\"width: 48.6654%;\"><strong>Biopsy shows myocyte destruction</strong></td>\n<td style=\"width: 48.6654%;\">Biopsy does not show myocyte destruction</td>\n</tr>\n</tbody>\n</table>\n<p><br /><strong>Anthracyclines</strong> like doxorubicin can result in a <strong>radiation recall reaction</strong>, where <strong>erythema and desquamation of skin</strong> are observed at sites of <strong>previous radiation injury.</strong> The risk of cardiotoxicity also increases with previous irradiation. Therefore, careful monitoring and dosage adjustments are required for doxorubicin.<br /><br />Other options :\u00a0<br /><br />Option B, C and D : Dexamethasone, aprepitant and amifostine are not used in the management of anthracycline induced cardiotoxicity.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An elderly patient with dementia is not compliant with oral medications. Which of the following will be beneficial in this case?",
    "choices": [
      {
        "id": 1,
        "text": "Donepezil"
      },
      {
        "id": 2,
        "text": "Rivastigmine"
      },
      {
        "id": 3,
        "text": "Galantamine"
      },
      {
        "id": 4,
        "text": "Memantine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Rivastigmine transdermal patch</strong> can be prescribed to patients with <strong>dementia</strong> who are <strong>non compliant on oral</strong> medications.</p>\n<p>Rivastigmine is a<strong> cholinesterase inhibitor </strong>that is available as a <strong>transdermal patch</strong> for use in <strong>alzheimer's disease</strong> and <strong>dementia</strong>. It can be applied for <strong>over 24 hours</strong>. <strong>Transdermal delivery</strong> <strong>reduces the fluctuation </strong>and <strong>avoids direct gastric irritation</strong> effects associated with <strong>oral formulations</strong>.<br /><br /><strong>Alzheimer's disease</strong> is the<strong> most common cause </strong>of <strong>dementia</strong> in the <strong>elderly</strong>. The characteristic feature of Alzheimer's is the <strong>degeneration of cholinergic neurons</strong> leading to <strong>reduced levels of acetylcholine</strong>. <br /><br />Treatment includes <strong>cholinesterase</strong> <strong>inhibitors</strong> like <strong>Donepezil</strong>, <strong>Rivastigmine</strong> and <strong>Galantamine</strong> and <strong>NMDA receptor antagonist</strong> like <strong>memantine</strong>. The <strong>cholinesterase inhibitors</strong> cause significant side effects such as<strong> nausea, vomiting, diarrhea </strong>and<strong> peripheral cholinergic effects</strong>, which can be avoided by using a transdermal formulation.<br /><br /><strong>Anticholinesterase drugs<br /><br /></strong></p>\n<table style=\"border-collapse: collapse; width: 100.046%; height: 156.789px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Reversible inhibitors</strong></td>\n<td style=\"width: 48.6654%; height: 22.3984px;\">\u00a0</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Carbamates</strong></td>\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Non-Carbamates</strong></td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\">Physostigmine, Neostigmine, Pyridostigmine, Rivastigmine</td>\n<td style=\"width: 48.6654%; height: 22.3984px;\">Edrophonium, Tacrine, Donepezil, Galantamine</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\">\u00a0</td>\n<td style=\"width: 48.6654%; height: 22.3984px;\">\u00a0</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Irreversible inhibitors</strong></td>\n<td style=\"width: 48.6654%; height: 22.3984px;\">\u00a0</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Carbamates</strong></td>\n<td style=\"width: 48.6654%; height: 22.3984px;\"><strong>Organophosphates</strong></td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 48.6654%; height: 22.3984px;\">Carbaryl, Propoxur</td>\n<td style=\"width: 48.6654%; height: 22.3984px;\">Dyflos, Echthiophate, Malathion, Diazinon, Tabun, Sarin, Soman</td>\n</tr>\n</tbody>\n</table>\n<p><br />Other options :<br /><br />Options A, C and D: Donepezil, galantamine and memantine are currently available in the oral form and transdermal formulations are under development and yet to be available in the market.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Sodium valproate has an inhibitory action at which of the following sites?",
    "choices": [
      {
        "id": 1,
        "text": "A"
      },
      {
        "id": 2,
        "text": "B"
      },
      {
        "id": 3,
        "text": "C"
      },
      {
        "id": 4,
        "text": "D"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Sodium valproate</strong> has an <strong>inhibitory action</strong> on the <strong>metabolism</strong> and <strong>degradation</strong> of <strong>GABA</strong>, and also<strong> increases its synthesis</strong>.<br /><br /><strong>Valproate</strong> is an <strong>anti-epileptic </strong>medication and also used as a <strong>mood stabilizer</strong> in <strong>bipolar disorder</strong>. Valproate <strong>acts via multiple mechanisms</strong>. It <strong>blocks</strong> <strong>both</strong> <strong>sodium</strong> and <strong>calcium</strong> <strong>channels</strong>. It <strong>prolongs sodium channel inactivation</strong> and <strong>attenuates calcium-mediated 'T' current</strong>. It <strong>inhibits metabolism and degradation</strong> of the inhibitory neurotransmitter <strong>GABA</strong> and <strong>increases its synthesis</strong> from <strong>glutamic acid</strong> (Option A). It also <strong>inhibits excitatory NMDA glutamate receptors</strong>. The <strong>repetitive firing</strong> caused by the <strong>depolarization of cortical or spinal cord neurons</strong> is <strong>inhibited</strong> by valproate.</p>\n<p>Valproate is a<strong>\u00a0broad spectrum antiseizure drug</strong> used in <strong>partial seizures, generalised tonic-clonic seziures (GTCS), absence seizures, myoclonic seziures</strong> and <strong>atonic seziures</strong>. It can be used in absence seizures, but it is preferred when the child also suffers from GTCS. It is the <strong>drug of choice</strong> for <strong>juvenile myoclonic epilepsy</strong>.\u00a0</p>\n<p>The<strong> side effects </strong>of valproate (mnemonic: VALPROATE)</p>\n<p><strong>V</strong>omiting<br /><strong>A</strong>lopecia<br /><strong>L</strong>iver toxicity<br /><strong>P</strong>ancreatitis<br /><strong>R</strong>ash<br /><strong>O</strong>besity<br /><strong>A</strong>norexia<br /><strong>T</strong>eratogenicity<br /><strong>E</strong>dema</p>\n<p>It causes <strong>congenital anomalies</strong> like <strong>neural tube defects (Spina Bifida)</strong>, <strong>clefts</strong>, and <strong>cardiac anomalies</strong>. The <strong>intelligence quotient</strong> score of school-going children who were <strong>exposed in utero to valproate</strong> is found <strong>reduced</strong>. It also contributes to <strong>poor cognitive development</strong> in children. <strong>Folate supplementation</strong> <strong>reduces</strong> the chances of <strong>neural tube defects.</strong></p>\n<p>Other options :\u00a0<br /><br />Option C : Drugs such as <strong>vigabatrine and tiagabine</strong> <strong>inhibit GABA reuptake</strong> by inhibiting the GABA reuptake transporter. <strong>Vigabatrine</strong> is the <strong>drug of choice</strong> for <strong>infantile spasms (West syndrome</strong>) seen in <strong>tuberous sclerosis</strong>.</p>\n<p>Option D : <strong>Flumazenil</strong> acts as an <strong>antagonist</strong> at the <strong>GABA receptor</strong> and is used as an <strong>antidote for benzodiazepine overdose</strong>. <strong>Benzodiazepines</strong> act by <strong>promoting GABA inhibition</strong> by <strong>binding to the GABA receptor</strong> itself and <strong>inhibiting nerve transmission</strong>.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/0d14e58f54894d9d9389bff9d61b97e6.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs acts via the ATP-binding cassette transporter?",
    "choices": [
      {
        "id": 1,
        "text": "Verapamil"
      },
      {
        "id": 2,
        "text": "Diltiazem"
      },
      {
        "id": 3,
        "text": "Nifedipine"
      },
      {
        "id": 4,
        "text": "Amlodipine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Verapamil</strong> is a <strong>potent inhibitor of P-glycoprotein drug transporter </strong>which belongs to the family of <strong>ATP-binding cassette (ABC) transporters</strong>.<br /><br />A group of <strong>primary active transporters</strong>, the <strong>ATP-binding cassette (ABC) family</strong>, hydrolyze ATP to export substrates across membranes. <strong>P-glycoprotein (P-gp)</strong> is an ATP-binding cassette (ABC) transporter, which acts as an<strong> efflux membrane transporter</strong>. It is responsible for<strong> limiting cellular uptake </strong>and the <strong>distribution of xenobiotics and toxic substances</strong>. P-glycoprotein is also called <strong>ABCB1 or MDR1</strong>, and it <strong>exports bulky neutral </strong>or <strong>cationic</strong> <strong>compounds</strong> <strong>from cells</strong>. <strong>MDR1</strong> <strong>exports</strong> many drugs as well. It is associated with multidrug resistance (MDR) to <strong>cancer chemotherapeutics</strong> through the <strong>multidrug resistance protein 1 or MDR1</strong>.<br /><br /><strong>Verapamil</strong> can cause<strong> interactions with drugs</strong> whose disposition is dependent upon P-glycoprotein. <strong>Drugs that inhibit P-glycoprotein</strong> are -</p>\n<ol>\n<li><strong>Clarithromycin</strong></li>\n<li><strong>Erythromycin</strong></li>\n<li><strong>Amiodarone</strong></li>\n<li><strong>Quinidine</strong></li>\n<li><strong>Verapamil</strong></li>\n<li><strong>Diltiazem</strong></li>\n<li><strong>Cyclosporine</strong></li>\n<li><strong>Itraconazole</strong></li>\n<li><strong>Propafenone</strong></li>\n<li><strong>Flecainide</strong>.</li>\n</ol>\n<p>P-glycoprotein pumps play a major role in the elimination of certain drugs such as <strong>digoxin</strong>. Drugs that inhibit P-glycoprotein can thereby decrease their elimination and lead to <strong>toxicity</strong>. For eg, digoxin is metabolized by P-glycoprotein, and drugs that inhibit it increase the plasma levels of digoxin and may result in toxicity.</p>\n<p><strong>Increased P-gp expression</strong>: <strong>Reduces the absorption</strong> of drugs that are substrates for P-gp.<br /><strong>Decreased P-gp expression</strong>: Leads to <strong>supratherapeutic plasma concentrations</strong> and drug toxicity.<br /><br />Other options :\u00a0<br /><br />Option B, C, and D: Although diltiazem, nifedipine, and amlodipine have been reported in the literature to act as p-glycoprotein inhibitors, verapamil is more potent and commonly used for p-glycoprotein inhibition in trials, and would be the best answer.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 12 year old boy presents with complaints of profuse watery stools and an elevated WBC count of 16000 cells/mm3. He has been on treatment with amoxicillin for the past 1 week. What is the treatment of choice for his condition?",
    "choices": [
      {
        "id": 1,
        "text": "Fidaxomycin"
      },
      {
        "id": 2,
        "text": "Clindamycin"
      },
      {
        "id": 3,
        "text": "Zanamivir"
      },
      {
        "id": 4,
        "text": "Cilastatin"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Oral Fidaxomicin </strong>is the antibiotic indicated for this patient's condition which is suggestive of\u00a0<em><strong>Clostridium difficile</strong>\u00a0</em>infection, characterized by <strong>profuse watery diarrhea </strong>and\u00a0<strong>leukocytosis</strong>\u00a0following long term antibiotic use such as <strong>ampicillin</strong>.<br /><br /><em>C difficle infection\u00a0</em>is most commonly associated with\u00a0<strong>prolonged antimicrobial use</strong>\u00a0which <strong>interferes</strong> <strong>with</strong> the <strong>commensal colonic microflora</strong>. The most commonly implicated antibiotics are\u00a0<strong>cephalosporins,\u00a0ampicillin,\u00a0clindamycin,\u00a0</strong>and<strong>\u00a0fluoroquinolones</strong>. Spores of toxigenic<em>\u00a0C. difficile</em>\u00a0when ingested, survive gastric acidity and colonize the lower intestinal tract. Here they produce two toxins:<strong> toxin A (an enterotoxin)</strong> and<strong> toxin B (a cytotoxin)</strong>. These toxins initiate processes that <strong>disrupt the epithelial-cell barrier function</strong>, <strong>diarrhea</strong>, and <strong>pseudomembrane</strong> <strong>formation</strong>.<em>\u00a0</em>The patient presents with <strong>non bloody diarrhea</strong>, <strong>fever</strong>, <strong>abdominal pain,</strong> and <strong>leukocytosis</strong>.<br /><br />Clinical features\u00a0can range from asymptomatic carriage to fulminant colitis.\u00a0</p>\n<ul>\n<li><strong>Nonsevere disease</strong>\u00a0-\u00a0Watery diarrhea (\u22653 loose stools in 24 hours) is the cardinal symptom.\u00a0Other manifestations include lower abdominal pain and cramping, low-grade fever, nausea, anorexia,\u00a0mucus, or occult blood in the stool.\u00a0Physical examination may demonstrate lower abdominal tenderness.\u00a0Unexplained leukocytosis in hospitalized patients (even in the absence of diarrhea) may reflect underlying CDI</li>\n<li><strong>Severe colitis -\u00a0</strong>Clinical manifestations of severe colitis include diarrhea, lower quadrant or diffuse abdominal pain, abdominal distention, fever, hypovolemia, lactic acidosis, hypoalbuminemia, elevated creatinine, and marked leukocytosis.</li>\n<li><strong>Fulminant colitis</strong>\u00a0- Characterized by hypotension or shock, ileus, or\u00a0<strong>megacolon.</strong></li>\n<li><strong>Recurrent disease -\u00a0</strong>resolution of CDI followed by recurrence of symptoms within two to eight weeks after treatment has been stopped<strong>\u00a0</strong></li>\n</ul>\n<div class=\"page\" title=\"Page 1108\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Nucleic acid amplification</strong>\u00a0tests including polymerase chain reaction (<strong>PCR</strong>) assays, for\u00a0<em>C. difficile</em>\u00a0<strong>toxin A or B gene</strong> <strong>in stool</strong>, are widely used diagnostically. <strong>Glutamate dehydrogenase</strong> is an enzyme immunoassay to detect\u00a0<em>C. difficile</em>\u00a0in stool. Confirmation of the presence of toxin in the stool in addition to PCR or glutamate dehydrogenase positivity is recommended.\u00a0</p>\n<p><strong>Oral vancomycin</strong>,\u00a0<strong>fidaxomicin,\u00a0</strong>and<strong>\u00a0metronidazole\u00a0</strong>are used in the management of this condition.\u00a0<strong>Fidaxomicin</strong> acts by <strong>inhibiting protein synthesis</strong> through the <strong>blockade of RNA polymerase</strong>.\u00a0<br /><br /><strong>Management of nonsevere to severe initial disease:</strong></p>\n<table style=\"height: 135px; width: 676px;\">\n<tbody>\n<tr>\n<td style=\"width: 293.438px;\">\n<p><strong>Nonsevere disease</strong></p>\nSupportive clinical data: White blood cell count \u226415,000 cells/mL and serum creatinine &lt;1.5 mg/dL</td>\n<td style=\"width: 353.969px;\">\n<ul>\n<li>Vancomycin 125 mg orally 4 times daily for 10 days,\u00a0<strong>OR</strong></li>\n<li><strong>Fidaxomicin</strong> 200 mg orally twice daily for 10 days</li>\n<li>If above agents are unavailable: Metronidazole\u00a0500 mg orally 3 times daily for 10 days</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 293.438px;\">\n<p><strong>Severe disease</strong></p>\nSupportive clinical data: White blood cell count &gt;15,000 cells/mL and/or serum creatinine \u22651.5 mg/dL</td>\n<td style=\"width: 353.969px;\">\u00a0\n<ul>\n<li>Vancomycin\u00a0125 mg orally 4 times daily for 10 days,\u00a0<strong>OR</strong></li>\n<li><strong>Fidaxomicin</strong> 200 mg orally twice daily for 10 days</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong><br />Management of recurrent disease:<br /></strong></p>\n<table style=\"height: 136px; width: 674px;\">\n<tbody>\n<tr>\n<td style=\"width: 300.734px;\">First recurrence</td>\n<td style=\"width: 344.672px;\">\n<ul>\n<li>If vancomycin was used for the initial episode: Vancomycin pulsed-tapered regimen:\n<ul>\n<li>125 mg orally 4 times daily for 10 to 14 days, then</li>\n<li>125 mg orally twice daily for 7 days, then</li>\n<li>125 mg orally once daily for 7 days, then</li>\n<li>125 mg orally every 2 or 3 days for 2 to 8 weeks,\u00a0<strong>OR</strong></li>\n</ul>\n<ul>\n<li>Fidaxomicin 200 mg orally twice daily for 10 days</li>\n</ul>\n</li>\n<li>If fidaxomicin or metronidazole was used for the initial episode: Vancomycin 125 mg orally 4 times daily for 10 days</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 300.734px;\">Second or subsequent recurrence</td>\n<td style=\"width: 344.672px;\">\u00a0\n<ul>\n<li>Vancomycin pulsed-tapered regimen (outlined above),\u00a0<strong>OR</strong></li>\n<li><strong>Fidaxomicin</strong> 200 mg orally twice daily for 10 days,\u00a0<strong>OR</strong></li>\n<li>Vancomycin followed by rifaximin:\n<ul>\n<li>Vancomycin 125 mg orally 4 times per day for 10 days, then</li>\n<li>Rifaximin 400 mg 3 times daily for 20 days,\u00a0<strong>OR</strong></li>\n</ul>\n</li>\n<li>FMT</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong><br />Management of fulminant disease -\u00a0</strong></p>\n<table style=\"height: 154px; width: 673px;\">\n<tbody>\n<tr>\n<td style=\"width: 265.938px;\">Initial episode</td>\n<td style=\"width: 378.469px;\">\n<ul>\n<li>Enteric vancomycin plus parenteral metronidazole:\n<ul>\n<li>Vancomycin\u00a0500 mg orally or via nasogastric tube 4 times daily,\u00a0<strong>AND</strong></li>\n<li>Metronidazole 500 mg intravenously every 8 hours</li>\n</ul>\n</li>\n<li>If ileus is present,\u00a0additional considerations include:\n<ul>\n<li>FMT (administered rectally)</li>\n<li>Rectal vancomycin (administered as a retention enema 500 mg in 100 mL normal saline per rectum; retained for as long as possible and readministered every 6 hours)</li>\n</ul>\n</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 265.938px;\">Recurrent episode</td>\n<td style=\"width: 378.469px;\">\u00a0\n<ul>\n<li>Antibiotics as for initial fulminant episode above</li>\n<li>Some favor FMT in the context of a first or second recurrence that presents as a fulminant episode</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Other options:</p>\n<p>Option B : <strong>Clindamycin\u00a0</strong>is implicated as a <strong>risk factor</strong> for development of clostridium difficile colitis and is not used to treat it.</p>\n<p>Option C : <strong>Zanamavir\u00a0</strong>is a neuraminidase inhibitor used against influenza A and B virus.</p>\n<p>Option D : <strong>Cilastatin\u00a0</strong>is a\u00a0<strong>reversible dehydropeptidase inhibitor\u00a0</strong>and used adjunctively with\u00a0<strong>imipenem\u00a0</strong>to prolong its action as it rapidly hydrolysed by\u00a0<strong>renal dehydropeptidase.\u00a0</strong>It is not used in the treatment of clostridium difficile colitis.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following mood stabilisers causes hepatotoxicity and hyperammonemia?",
    "choices": [
      {
        "id": 1,
        "text": "Lithium"
      },
      {
        "id": 2,
        "text": "Valproate"
      },
      {
        "id": 3,
        "text": "Carbamazepine"
      },
      {
        "id": 4,
        "text": "Topiramate"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Valproate</strong> is a <strong>mood stabilizer</strong> with the side effect of <strong>hepatotoxicity</strong> and <strong>hyperammonemia</strong>.<br /><br /><strong>Valproate</strong> is an<strong> anti-epileptic medication </strong>and\u00a0also used as a <strong>mood stabilizer </strong>in <strong>manic</strong> <strong>episodes</strong> as well as in <strong>bipolar disorder.</strong> The <strong>repetitive firing</strong> caused by the <strong>depolarization of cortical or spinal cord neurons</strong> is <strong>inhibited</strong> by valproate. It also <strong>prolongs</strong> the <strong>sodium channel inactivation</strong>. Valproate can cause an<strong> idiosyncratic hepatic toxicity</strong> and <strong>interfere </strong>with <strong>conversion of ammonia to urea</strong> leading to <strong>hyperammonemia</strong>. Valproate is <strong>contraindicated</strong> in patients with<strong> genetic defects in urea metabolism</strong>.<br /><br />Valproate therapy <strong>reduces carnitine levels in tissues</strong>, potentially impacting mitochondrial function and leading to <strong>hyperammonemia</strong> and <strong>microvesicular steatosis</strong>. Genetic factors also play a role, as individuals who are heterozygous for mutations in the gamma polymerase gene, which is primarily present in mitochondria, are more susceptible to valproate-induced liver damage. <strong>Intravenous administration</strong> of <strong>carnitine</strong> can be used to manage this condition.<br /><br />The side effects of valproate (mnemonic: <strong>VALPROATE</strong>)</p>\n<p><strong>V</strong>omiting<br /><strong>A</strong>lopecia<br /><strong>L</strong>iver toxicity<br /><strong>P</strong>ancreatitis<br /><strong>R</strong>ash<br /><strong>O</strong>besity<br /><strong>A</strong>norexia<br /><strong>T</strong>eratogenicity<br /><strong>E</strong>dema</p>\n<p>It causes <strong>congenital anomalies</strong> like <strong>neural tube defects</strong> (Spina Bifida), clefts, and <strong>cardiac anomalies</strong>. The<strong> intelligence quotient</strong> score of school-going children who were exposed in utero to valproate is found <strong>reduced</strong>. It also contributes to<strong> poor cognitive development</strong> in children. <strong>Folate supplementation</strong> reduces the chances of neural tube defects.</p>\n<p>Other options :</p>\n<p>Option A : <strong>Lithium</strong> is a<strong> mood stabilizer</strong> with a very <strong>narrow therapeutic index</strong> and is the <strong>first line</strong> of management in<strong> bipolar disorder</strong>. Its <strong>adverse effects </strong>can be <strong>acute</strong> such as<strong> tremors, ataxia, weakness, polyuria, polydipsia</strong> or <strong>chronic</strong> such as <strong>nephrogenic diabetes insipidus, thyroid dysfunction</strong>, and <strong>hyperparathyroidism</strong>. It is not associated with hepatotoxicity or hyperammonemia.\u00a0<br /><br />Option C : <strong>Carbamazepine\u00a0</strong>is a <strong>sodium channel blocker</strong> used in the management of <strong>complex partial seizures, GTCS, simple partial seizures</strong> and <strong>trigeminal neuralgia</strong>. It is known to be <strong>hepatotoxic</strong> but is<strong> not associated </strong>with <strong>hyperammonemia</strong>. Other adverse effects include <strong>hypersensitivity</strong> reactions, <strong>eosinophilia</strong>, <strong>agranulocytosis</strong>, <strong>aplastic</strong> <strong>anemia</strong>, <strong>hyponatremia</strong> and <strong>stevens-johnson syndrome</strong>.<br /><br />Option D : <strong>Topiramate\u00a0</strong>is an<strong> anti epileptic </strong>and <strong>non-opioid pain medication</strong> which is associated with <strong>significant weight loss</strong> of <strong>up to 7%</strong> as a side effect.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following pathogens is correctly matched with its intrinsic drug resistance?",
    "choices": [
      {
        "id": 1,
        "text": "Aspergillus niger - Voriconazole"
      },
      {
        "id": 2,
        "text": "Candida krusei - Fluconazole"
      },
      {
        "id": 3,
        "text": "Candida Glabrata - Amphotericin B"
      },
      {
        "id": 4,
        "text": "Sporothrix - Itraconazole"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Among the given options, <strong>Candida krusei </strong>shows an <strong>intrinsic resistance</strong> to <strong>fluconazole</strong>. <br /><br />The <strong>primary</strong> or <strong>intrinsic resistance</strong> of <strong>C. krusei </strong>to <strong>azoles</strong> (<strong>fluconazole</strong> and <strong>itraconazole</strong>) is mediated through <strong>reduced susceptibility of the target enzyme</strong> <strong>(lanosterol 14\u03b1-demethylase) to inhibition</strong> by these drugs. However, <strong>improved susceptibility</strong> is seen with <strong>newer generation azoles</strong> such as <strong>voriconazole</strong>.</p>\n<p><strong>Life-threatening systemic infections</strong> caused by <strong>Candida</strong> and <strong>Aspergillus</strong> species are usually seen in <strong>severely ill</strong> and <strong>immunocompromised</strong> patients such as <strong>HIV</strong>, <strong>chemotherapy</strong>-<strong>induced</strong> <strong>neutropenia</strong>, and <strong>transplant</strong> <strong>recipients</strong> on <strong>immunosuppressants</strong>. <strong>C. albicans</strong> and <strong>C. dubliniensis</strong> are <strong>most susceptible</strong> to <strong>currently available azoles</strong>, <strong>C. glabrata</strong> is <strong>less susceptible</strong>, whereas <strong>C. krusei</strong> is <strong>intrinsically resistant</strong> to <strong>fluconazole</strong>. Resistance occurs due to <strong>overexpression or point mutation</strong> in the gene encoding the target enzyme<strong> lanosterol 14\u03b1-demethylase</strong>. <strong>Voriconazole</strong> is the preferred therapy for <strong>multi-drug resistant infection</strong> with<strong> C. krusei</strong>.</p>\n<p><strong>C. albicans</strong> and <strong>C. glabrata</strong> (Option C) showing <strong>resistance to Amphotericin B</strong> has been increasingly reported over the past several years. But this is a <strong>secondary resistance</strong> due to <strong>alteration</strong> or a <strong>decrease</strong> in the<strong> amount of ergosterol</strong> in the cell membrane. Amphotericin B is indicated to treat C. glabrata that has developed resistance to azoles.</p>\n<p><strong>Aspergillus fumigatus</strong>, the most common species to cause Aspergillus infection worldwide, also shows an <strong>intrinsic resistance to fluconazole</strong>. It is <strong>susceptible to echinocandins</strong> like micafungin, which acts by <strong>inhibiting beta-(1,3)-D-glucan synthase</strong>, an enzyme necessary for the synthesis of the cell wall.</p>\n<p>Other options<br /><br />Option A : <strong>Aspergillus niger</strong> is a common cause of <strong>otomycosis</strong> and is<strong> susceptible to azoles</strong> like <strong>voriconazole</strong>, amphotericin B, and echinocandins.<br /><br />Option D : The <strong>drug of choice</strong> for treatment of <strong>sporotrichosis</strong> is <strong>itraconazole</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A child was receiving a blood transfusion. At what serum iron level will desferrioxamine be administered to him?",
    "choices": [
      {
        "id": 1,
        "text": "350 mcg/dL"
      },
      {
        "id": 2,
        "text": "400 mcg/dL"
      },
      {
        "id": 3,
        "text": "450 mcg/dL"
      },
      {
        "id": 4,
        "text": "500 mcg/dL"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>IV desferrioxamine</strong> (also known as\u00a0<strong>deferoxamine)</strong>\u00a0is indicated when<strong> serum iron levels</strong> are <strong>greater than 500 mcg/dL</strong> in cases of <strong>iron toxicity.</strong></p>\n<p><strong>Desferrioxamine</strong> is selectively used as a <strong>chelating agent </strong>to manage cases of <strong>acute iron poisoning,</strong> <strong>hemochromatosis</strong>, and patients with <strong>iron</strong> <strong>overload</strong> from <strong>repetitive blood transfusions</strong>. Desferrioxamine can be <strong>administered intramuscularly</strong>, <strong>intravenously</strong>, or <strong>subcutaneously</strong> but <strong>not orally</strong>.</p>\n<p><strong>Deferiprone</strong> and <strong>deferasirox</strong> are both <strong>oral drugs</strong> and can be given in<strong> transfusion related siderosis</strong> but are less effective than desferrioxamine. Although, they can be preferred because of the ease of administration through oral route and multiple transfusions required for beta thalassemia patients.<br /><br />Iron exhibits<strong> toxic effects</strong> by <strong>hydration of the ferric (F<sup>3+</sup>) ion</strong> which<strong> generates H<sup>+</sup></strong>. Non transferrin bound iron catalyses <strong>free radical formation </strong>which causes <strong>mitochondrial injury, lipid peroxidation, increased capillary permeability, vasodilation, and organ toxicity</strong>.<br /><br /><strong>Clinical features</strong> of iron toxicity include<strong> initial nausea, vomiting, abdominal pain</strong> and <strong>diarrhea</strong>. In <strong>severe cases </strong>there is<strong> high anion gap metabolic acidosis</strong>, <strong>cardiovascular and CNS depression</strong>, <strong>hepatitis</strong>, <strong>coagulopathy</strong>, and <strong>seizures</strong>.<br /><br />In the case of<strong> toxic iron ingestion</strong>, <strong>radiopaque iron tablets</strong> may be seen on <strong>abdominal x-ray</strong>.</p>\n<p><strong>Management</strong> of iron toxicity includes the following :\u00a0</p>\n<ul>\n<li><strong>Whole-bowel irrigation</strong> for<strong> large ingestions</strong>, <strong>endoscopy</strong> and <strong>gastrostomy</strong> if clinical toxicity and large number of tablets are still visible on x-ray.</li>\n<li><strong> IV hydration</strong>.</li>\n<li><strong> Sodium bicarbonate</strong> for <strong>acidemia</strong>.</li>\n<li><strong>IV desferrioxamine</strong> for <strong>systemic</strong> <strong>toxicity</strong>, <strong>iron level &gt;90 \u03bcmol/L</strong> (<strong>500</strong> <strong>\u03bcg/dL</strong>).</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient on fluoxetine was started on a pain control drug for neuropathic pain. He developed an episode of syncope after 2 weeks. ECG reveals QT interval of 477 ms. Which of the following is the causative drug?",
    "choices": [
      {
        "id": 1,
        "text": "Methadone"
      },
      {
        "id": 2,
        "text": "Morphine"
      },
      {
        "id": 3,
        "text": "Meperidine"
      },
      {
        "id": 4,
        "text": "Propoxyphene"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Methadone</strong> is the <strong>causative drug</strong> for this patient's presentation of <strong>syncope</strong> and<strong> prolonged QT interval </strong>after <strong>coadministration</strong> other QT prolonging drugs such as <strong>fluoxetine</strong>.<br /><br />Unlike other opioids, <strong>QT prolongation</strong> is primarily a<strong> side effect of methadone</strong>, which is <strong>additive</strong> <strong>with other agents</strong> known to cause <strong>QT prolongation</strong> such as <strong>fluoxetine</strong>. <strong>Serious cardiac arrhythmias </strong>including <strong>torsades de pointes</strong> have been noted with methadone use.<strong> Normal QTc </strong>is about <strong>440 ms</strong>. Values of <strong>more than 440 ms in males</strong> and <strong>460 ms in females</strong> are considered to be <strong>prolonged</strong>. QT prolongation can present as <strong>syncope</strong> or <strong>cardiac arrest</strong>.<br /><br /><strong>Methadone</strong> is a <strong>synthetic opioid</strong> that is <strong>chemically different</strong> but has<strong> similar pharmacological</strong> <strong>action</strong> to that of <strong>morphine</strong> (Option B). It is a <strong>long-acting mu-opioid receptor agonist</strong>. Although an effective analgesic, the <strong>primary use</strong> of methadone hydrochloride is <strong>detoxification and maintenance</strong> <strong>therapy</strong> treatment for<strong> opioid use disorder</strong>. Methadone is also used for the <strong>management of chronic pain</strong>.<br /><br /><strong>Side effects </strong>of methadone are <strong>similar to that of morphine </strong>such as <strong>lethargy, constipation, respiratory depression, and hypotension</strong>. Like other opioids, methadone will produce <strong>tolerance and dependence</strong>. Development of physical dependence during the long-term administration of methadone can be demonstrated following abrupt drug withdrawal or administration of an opioid antagonist.\u00a0<br /><br />Other options :\u00a0<br /><br />Option B : Morphine is not associated with QT prolongation.</p>\n<p>Option C : <strong>Meperidine</strong>, also known as <strong>pethidine</strong>, though chemically unrelated to morphine interacts with \u00b5 opioid receptors and its actions are blocked by naloxone. Apart from usual opioid side effects, pethidine produces some <strong>atropinic effects</strong> like dry mouth, blurred vision, tachycardia. Pethidine injected in patients receiving a selective serotonin reuptake inhibitor (SSRI) may produce<strong> serotonin syndrome</strong>. It is occasionally used to <strong>control shivering during recovery from anaesthesia</strong>.</p>\n<p>Option D : <strong>Propoxyphene</strong> is a<strong> methadone analogue </strong>that was used to treat mild-tomoderate pain. Due to reports of <strong>cardiotoxicity</strong>, it was <strong>withdrawn</strong> <strong>in UK, Europe, and USA</strong> and it was<strong> banned in India in 2013</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "All of the following side effects are more commonly seen with carbamazepine than oxcarbazepine except",
    "choices": [
      {
        "id": 1,
        "text": "Rashes"
      },
      {
        "id": 2,
        "text": "Hyponatremia"
      },
      {
        "id": 3,
        "text": "Blood dyscrasia"
      },
      {
        "id": 4,
        "text": "Hepatitis"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Hyponatremia</strong> occurs <strong>more frequently</strong> in the case of <strong>oxcarbazepine</strong> than carbamazepine.</p>\n<p>Both carbamazepine and oxcarbazepine are<strong> sodium-channel blockers </strong>that <strong>stabilize neuronal membranes</strong>. Oxcarbazepine is the 10-keto analog of carbamazepine and and cannot form an epoxide metabolite. <strong>Carbamazepine</strong> <strong>potentiates</strong> the action of<strong> antidiuretic hormone</strong> (ADH). It can result in <strong>water retention</strong> with decreased osmolarity and <strong>hyponatremia</strong>, especially in elderly patients with cardiac disease. Although <strong>hyponatremia may occur more commonly with oxcarbazepine</strong> than with carbamazepine, most adverse effects of oxcarbazepine are similar to those of carbamazepine. <br /><br />Carbamazepine and oxcarbazepine can cause <strong>leukopenia, aplastic anemia, hepato-toxicity</strong> in the elderly.\u00a0<br /><br /><strong>Oxcarbazepine</strong> shows <strong>lesser hypersensitivity</strong> reaction. Hence,<strong> rashes (option A) are more commonly seen with carbamazepine </strong>than with oxcarbazepine.<br /><br />Studies have shown that <strong>carbamazepine</strong> <strong>elevates enzyme gamma-glutamyl transpeptidases (GGT) more frequently</strong> than oxcarbazepine because of <strong>enzyme</strong> <strong>P450 induction</strong>. Hepatotoxicity from oxcarbazepine occurs less commonly compared to carbamazepine (Option D).\u00a0<br /><br /><strong>Side effects of carbamazepine</strong> therapy include: <strong>mnemonic: HEADS</strong></p>\n<p><strong>H</strong>ypersensitivity reactions<br /><strong>E</strong>osinophilia<br /><strong>A</strong>granulocytosis: report symptoms like sore throat/fever<br /><strong>A</strong>plastic anemia<br /><strong>A</strong>taxia<br /><strong>D</strong>ilutional hyponatremia<br /><strong>D</strong>iplopia, blurred vision<br /><strong>S</strong>plenomegaly<br /><strong>S</strong>tevens-Johnson syndrome</p>\n<p><strong>Carbamazepine</strong> is most effective in <strong>complex partial seizures</strong>. It is also used in <strong>GTCS</strong> and <strong>simple partial seizures</strong>, <strong>trigeminal and related neuralgias</strong>, and <strong>manic depressive psychosis. Oxcarbazepine</strong> has been used to treat<strong> intractable trigeminal neuralgia refractory</strong> to other anticonvulsants.\u00a0</p>\n<p>Mechanism of action of some common antiepileptics:</p>\n<table style=\"border-collapse: collapse; width: 51.1244%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 37.3106%;\">Mechanism of action</td>\n<td style=\"width: 62.6894%;\">Antiepileptics</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">Sodium-channel blockers</td>\n<td style=\"width: 62.6894%;\">\n<p>Phenytoin</p>\n<p>Carbamazepine, Oxcarbamazepine</p>\n<p>Eslicarbazepine</p>\n<p>Lamotrigine</p>\n<p>Topiramate</p>\n<p>Felbamate</p>\n<p>Valproate</p>\n<p>Rufinamide</p>\n<p>Levetiracetam</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">Calcium-channel blockers</td>\n<td style=\"width: 62.6894%;\">\n<p>Valproate</p>\n<p>Lamotrigine</p>\n<p>Ethosuximide</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">GABA A receptor modulators</td>\n<td style=\"width: 62.6894%;\">\n<p>Benzodiazepines</p>\n<p>Phenobarbital</p>\n<p>Felbamate</p>\n<p>Primidone</p>\n<p>Topiramate</p>\n<p>Carbamazepine, Oxcarbamazepine</p>\n<p>Stiripentol</p>\n<p>Clobazam</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">GABA uptake inhibitors</td>\n<td style=\"width: 62.6894%;\">\n<p>Tiagabine</p>\n<p>Vigabatrin</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">NMDA receptor antagonist</td>\n<td style=\"width: 62.6894%;\">Felbamate</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">AMPA/Kainate receptor antagonist</td>\n<td style=\"width: 62.6894%;\">\n<p>Phenobarbital</p>\n<p>Topiramate</p>\n<p>Perampanel</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">HCN channel activity enhancers</td>\n<td style=\"width: 62.6894%;\">Lamotrigine</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">Inhibitors of brain carbonic anhydrase</td>\n<td style=\"width: 62.6894%;\">\n<p>Acetazolamide</p>\n<p>Zonisamide</p>\n<p>Topiramate</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 37.3106%;\">Potassium-channel openers</td>\n<td style=\"width: 62.6894%;\">\n<p>Retigabine</p>\n<p>Topiramate</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with hemophilia on antiretroviral therapy is brought in altered mental status following complaints of nausea, vomiting and headache. Which of the following medications was he taking?",
    "choices": [
      {
        "id": 1,
        "text": "Lopinavir"
      },
      {
        "id": 2,
        "text": "Tipranavir"
      },
      {
        "id": 3,
        "text": "Darunavir"
      },
      {
        "id": 4,
        "text": "Ritonavir"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>This patient was most likely taking <strong>tipranavir</strong>, as it is known to be associated with an <strong>increased risk of intracranial hemorrhage and hepatotoxicity </strong>which is the likely cause of <strong>altered mental status</strong> in this patient with <strong>hemophilia</strong> following complaints of <strong>nausea, vomiting and headache</strong>.<br /><br /><strong>Tipranavir\u00a0</strong>is a <strong>protease inhibitor (PI) </strong>used in patients who are resistant to other\u00a0PIs. It is often combined with <strong>ritonavir,\u00a0</strong>to achieve better therapeutic outcomes. It should be avoided in patients with\u00a0<strong>head trauma </strong>or\u00a0<strong>bleeding diathesis</strong>, such as <strong>hemophilia</strong> as it is associated with an <strong>increased risk of intracranial</strong> <strong>hemorrhage</strong>. Other common adverse effects of tipranavir include nausea, vomiting, diarrhea, abdominal pain, urticarial or maculopapular rash, and liver toxicity.</p>\n<table style=\"border-collapse: collapse; width: 49.1969%; height: 134.39px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\"><strong>Antiretroviral drug</strong></td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\"><strong>Mechanism of action</strong></td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Nucleotide/ nucleoside reverse transcriptase inhibitors</td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Inhibits reverse transcriptase</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Non-nucleoside reverse transcriptase inhibitors</td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Inhibits reverse transcriptase by binding to an allosteric site of the enzyme</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\"><strong>Protease inhibitors</strong></td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\"><strong>Inhibits the viral protease enzyme necessary to produce mature virions upon budding from the host membrane.</strong></td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Entry inhibitors</td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">\n<p>Interferes with binding, fusion, and entry of HIV -1 into the cell by blocking a target.</p>\n<p>Maraviroc works by targetting CCR5, a coreceptor located on human helper T-cells</p>\n</td>\n</tr>\n<tr style=\"height: 22.3984px;\">\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Integrase inhibitors</td>\n<td style=\"width: 50%; height: 22.3984px; text-align: center;\">Inhibits the viral enzyme integrase, which is responsible for the integration of viral DNA into the DNA of the infected cell.</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Other Options :</strong>\u00a0</p>\n<p>Option A, C and D : Lopinavir, Darunavir and Ritonavir are protease inhibitors that can cause nausea and vomiting, although they are not contraindicated in patients with bleeding diathesis and not associated with an increased risk of intracranial hemorrhage.</p>\n<p><strong><br /></strong>The illustration below shows the mechanism of action of various antiretroviral drugs.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/a35d3bc243d84eabab61ffc2580066dcx769x673.JPEG"
    ]
  },
  {
    "text": "A 60-year-old patient with chronic kidney disease suddenly develops chest pain and palpitations. He had previously complained about feeling weak for the past week. Serum potassium was found to be 6.5mEq/L. Which of the following is likely to be found in this patients ECG?",
    "choices": [
      {
        "id": 1,
        "text": "Tall peaked T waves"
      },
      {
        "id": 2,
        "text": "Flat T waves"
      },
      {
        "id": 3,
        "text": "Tall QRS complexes"
      },
      {
        "id": 4,
        "text": "Prolonged PR intervals"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>Management of hyperkalemia involves an immediate reversal of cardiac effects by administration of <strong>10mL of 10% calcium gluconate intravenously</strong>. This leads to the reversal of the depolarization blockade due to hyperkalemia. Redistributing the excess potassium by administering <strong>10U of intravenous insulin </strong>followed by <strong>50mL of 50% dextrose</strong> can also be given, as insulin facilitates the intracellular shift of potassium. <strong>Beta-2-agonists</strong> can also be used in the management of hyperkalemia. But patients with end-stage renal disease are resistant to beta-2-agonists and hence must be used with caution.\u00a0Removal of potassium can be done using <strong>cation exchange resins</strong> like <strong>patiromer </strong>and<strong> sodium polystyrene sulfonate</strong>,<strong> diuretics</strong>,<strong>\u00a0</strong>and <strong>dialysis.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/1d540d18f4024d5cb2c7fa069efee6a3x1280x1585.JPEG"
    ]
  },
  {
    "text": "Which of the following drugs can be used in diabetic neuropathy, post herpetic neuralgia and spinal cord injury?",
    "choices": [
      {
        "id": 1,
        "text": "Amitriptyline"
      },
      {
        "id": 2,
        "text": "Phenytoin"
      },
      {
        "id": 3,
        "text": "Carbamazepine"
      },
      {
        "id": 4,
        "text": "Pregabalin"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Pregabalin</strong> can be used for <strong>diabetic neuropathy,</strong> <strong>post herpetic neuralgia</strong> and <strong>spinal cord injury</strong>. Although <strong>amitriptyline</strong> can also be used for these conditions, <strong>pregabalin</strong> is found to be <strong>recommended</strong> over amitriptyline considering <strong>safety and efficacy </strong>and hence is the best option.</p>\n<p><strong>Pregabalin</strong> is an <strong>anti</strong>-<strong>epileptic</strong> drug. Its <strong>analgesic effect</strong> is mediated by <strong>binding</strong> <strong>to \u03b12\u03b4</strong>, a <strong>protein</strong> that is a <strong>subunit</strong> of <strong>voltage-gated calcium channels</strong> and causes a <strong>decrease in glutamate release</strong> at <strong>excitatory synapses</strong>. Decreased neurotransmitter release is associated with <strong>reduced neuronal hyperexcitability</strong>. It is used in the management of <strong>neuropathic pain</strong> <strong>associated with diabetic peripheral neuropathy</strong>, <strong>spinal cord injury</strong> or <strong>postherpetic neuralgia</strong>.\u00a0</p>\n<p>Currently, only <strong>duloxetine and pregabalin</strong> are <strong>approved by the U.S. Food and Drug Administration</strong> and the European Medicines Agency to treat <strong>painful diabetic neuropathy</strong>.\u00a0Diabetic Neuropathy is the <strong>most common cause of peripheral neuropathy</strong> in <strong>developed countries</strong>. <strong>Risk factors</strong> include <strong>long-standing, poorly controlled DM</strong> and the <strong>presence</strong> <strong>of</strong> <strong>retinopathy and nephropathy</strong>.</p>\n<p><strong>Side effects</strong> of <strong>pregabalin</strong> include <strong>sedation</strong> and <strong>peripheral edema</strong>.</p>\n<p>Other options :\u00a0</p>\n<p>Option A : <strong>Tricyclic antidepressants (TCAs)</strong> such as <strong>amitriptyline</strong> are used in the <strong>treatment of several pain conditions</strong> such as <strong>diabetic neuropathy, post herpetic neuralgia</strong> and following <strong>spinal cord injury</strong>. Their mechanism of action is <strong>inhibition of norepinephrine and serotonin reuptake.</strong> Although both pregabalin and amitriptyline are among the first line drugs for neuropathic pain, amitriptyline would be the <strong>next best option</strong> in this question, owing to its <strong>side effect profile</strong> and good yet <strong>controversial efficacy in pain control</strong>. It is a <strong>non FDA approved</strong> <strong>drug</strong> for <strong>diabetic neuropathy (off label indication). </strong>Side effects associated with amitriptyline include <strong>anticholinergic side effects</strong> (dry mouth, tachycardia, hyperthermia), <strong>cardiac effects (arrhythmias)</strong> and <strong>sedation</strong>.</p>\n<p>Option B : <strong>Phenytoin</strong> is an <strong>antiepileptic</strong> drug that is not used in the treatment of pain.</p>\n<p>Option C :\u00a0<strong>Carbamazepine</strong> is an <strong>iminostilbine</strong> <strong>derivative</strong>. It <strong>blocks voltage-activated sodium channels</strong>, slowing their rate of recovery and limiting the repetitive firing of action potentials. It is used in the treatment of <strong>generalized, focal-to-bilateral and idiopathic tonic-clonic seizures, focal seizures, neuropathic pain</strong> associated with <strong>trigeminal and glossopharyngeal neuralgias</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following antibiotics acts by inhibiting the 50s ribosome?",
    "choices": [
      {
        "id": 1,
        "text": "Aztreonam"
      },
      {
        "id": 2,
        "text": "Daptomycin"
      },
      {
        "id": 3,
        "text": "Linezolid"
      },
      {
        "id": 4,
        "text": "Rifampicin"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Linezolid</strong> is a <strong>protein synthesis inhibitor</strong> that acts by <strong>inhibiting</strong> the<strong> 50s ribosomal</strong> <strong>subunit</strong>.<br /><br />Linezolid binds to the <strong>P site</strong> of the <strong>50s ribosomal subunit</strong> and <strong>inhibits bacterial protein synthesis.</strong> It is an <strong>oxazolidinone</strong> that is active against <strong>various resistant organisms</strong> including <strong>MRSA</strong>. It has <strong>excellent</strong> <strong>oral bioavailability</strong>. Linezolid is used to treat infections caused by <strong>gram-positive bacteria</strong>, particularly <strong>vancomycin-resistant enterococcus </strong>and <strong>methicillin-resistant Staphylococcus aureus</strong>. Linezolid is also approved for the treatment of <strong>community-acquired pneumonia </strong>due to<strong> S. pneumoniae</strong> and <strong>nosocomial pneumonia</strong> due to <strong>S. aureus.</strong><br /><br />The <strong>intrinsic resistance</strong> of <strong>gram-negative bacteria </strong>to linezolid is mediated by <strong>endogenous efflux pumps.</strong><br /><br />Linezolid is associated with the <strong>side effect of myelosuppression </strong>(anemia, leukopenia, pancytopenia, and thrombocytopenia). <strong>Thrombocytopenia is the most common side effect</strong>. Linezolid has<strong> MAOI (monoamine oxidase inhibitors) activity </strong>and therefore can <strong>precipitate serotonin syndrome with concomitant use of SSRI (paroxetine) </strong>or with other <strong>serotonergic medications.\u00a0</strong><strong><br /><br /></strong>Other adverse effects include <strong>peripheral neuropathy, optic neuropathy, lactic acidosis</strong>.<br /><br />Other options :\u00a0<br /><br />Option A : <strong>Aztreonam</strong> is a <strong>monobactam</strong>, and acts similar to penicillin by<strong> inhibiting peptiglycan crosslinking </strong>and inhibiting bacterial cell wall synthesis.</p>\n<p>Option B : <strong>Daptomycin</strong> is a <strong>cyclic lipopeptide</strong> antibiotic. It acts by<strong> depolarising bacterial membranes</strong> resulting in loss of membrane potential and cell death.\u00a0</p>\n<p>Option D : <strong>Rifampicin\u00a0</strong>is an anti tubercular antibiotic that acts by\u00a0<strong>inhibiting bacterial DNA-dependent RNA polymerase.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/daaf90ecdf2b4851873eddbe9c1c2392x1280x1258.JPEG"
    ]
  }
];
        let quizName = '058 Pharmacology Ini-Cet 2023';
        let hierarchy = ["Marrow", "PYQs", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>